LivingGLP1
Network meta-analysis

Serious adverse events

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
211
Randomized trials
60
Treatments
140,620
Participants
17,869
Events

In plain language

Across 211 trials with 140,620 participants, 2 of 59 treatments had a clearly better result than placebo on serious adverse events, and for 57 the evidence could not tell them apart from placebo. The most favorable estimate was for Liraglutide plus canagliflozin injection: hazard ratio (from event counts) 0.26 (95% credible interval 0.00 to 7.60).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
ALBI_SCBEIN_SCBGM050_SCBOFANG_SCCANAGLIFLOZINCANALIRA_SCCOTA_SCDANU_PODAPAEXEN_SCDAPAGLIFLOZINDULAMACU_SCDULA_SCECC500_POECNO_SCEFPE_SCEFSUBA_SCEMPAGLIFLOZINEXENER_SCEXENIMP_IMPLANTEXENROSI_SCEXEN_SCGLIBENCLAMIDEGLIMEPIRIDEGLP1RE_SCHRS7535_POICOSEMA_SCIDEGLIRA_SCIGLARLIXI_SCINS_ASPARTINS_DEGLUDECINS_DETEMIRINS_GLARGINEINS_ICODECINS_LISPROINS_PREMIXLINAGLIPTINLIRA_SCLIXI_SCLOTI_POMAZD_SCMETFORMINORFO_POOTHER_ACTIVE_additional_OADOTHER_ACTIVE_basal_bolus_insulinOTHER_ACTIVE_investigator_choice_oral_drugOTHER_ACTIVE_macupatideOTHER_ACTIVE_sulfonylureaPEGLOX_SCPIOGLITAZONEPLACEBORETA_SCROSIGLITAZONESAFIGL_POSEMA_POSEMA_SCSITAGLIPTINSTANDARD_CARETASP_SCTIRZ_SCVISEPE_SC
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.
0.010.020.050.10.20.250.51245102050100← favors treatmentfavors reference →Liraglutide plus canagliflozin i…SulfonylureaMazdutide injectionEcc500 poMacupatideBeinaglutide injectionEmpagliflozinLinagliptinPremixed insulinInvestigator choice oral drugBasal bolus insulinGLP-1 receptor agonist (liraglut…Tirzepatide injectionInsulin degludecMetforminInsulin glargine with lixisenati…Liraglutide injectionInsulin degludec with liraglutid…Dulaglutide injectionSemaglutide tabletAdditional oadTaspoglutide injectionExenatide injectionInsulin glargineStandard care or no added treatm…Semaglutide injectionEfpe scSitagliptinInsulin detemirExenatide extended release injec…Efsubaglutide alfa injectionExenatide extended release and d…Albiglutide injectionGlimepirideLixisenatide injectionCotadutide injectionPolyethylene glycol loxenatide i…Safiglipron (HRS-7535) tabletGlibenclamideCanagliflozinExenatide and rosiglitazone inje…DapagliflozinRosiglitazoneOrforglipron tabletRetatrutide injectionInsulin aspart (prandial)Visepegenatide injectionInsulin lispro (prandial)Ecnoglutide injectionInsulin icodec with semaglutide …Loti poBofanglutide (GZR18) injectionDanuglipron tabletInsulin icodecExenimp implantPioglitazoneHRS-7535 tabletDulaglutide with macupatide inje…Bgm050 sc
Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.
Effects of each treatment versus Placebo
TreatmentBayesian HR (95% CrI)95% prediction intervalFrequentist HR (95% CI)Verdict
Liraglutide plus canagliflozin injection
CANALIRA_SC
0.26 (0.00 to 7.60)0.00 to 7.87Unclear
Sulfonylurea
OTHER_ACTIVE_sulfonylurea
0.33 (0.05 to 1.56)0.05 to 1.61Unclear
Mazdutide injection
MAZD_SC
0.41 (0.13 to 1.16)0.12 to 1.22Unclear
Ecc500 po
ECC500_PO
0.45 (0.00 to 34.23)0.00 to 34.48Unclear
Macupatide
OTHER_ACTIVE_macupatide
0.48 (0.00 to 21.07)0.00 to 21.37Unclear
Beinaglutide injection
BEIN_SC
0.51 (0.01 to 33.28)0.01 to 34.25Unclear
Empagliflozin
EMPAGLIFLOZIN
0.55 (0.01 to 43.89)0.01 to 42.39Unclear
Linagliptin
LINAGLIPTIN
0.60 (0.01 to 46.03)0.01 to 47.63Unclear
Premixed insulin
INS_PREMIX
0.65 (0.39 to 1.05)0.36 to 1.14Unclear
Investigator choice oral drug
OTHER_ACTIVE_investigator_choice_oral_drug
0.71 (0.45 to 1.13)0.41 to 1.22Unclear
Basal bolus insulin
OTHER_ACTIVE_basal_bolus_insulin
0.71 (0.33 to 1.49)0.32 to 1.59Unclear
GLP-1 receptor agonist (liraglutide, exenatide, exenatide ER, albiglutide or dulaglutide) injection
GLP1RE_SC
0.72 (0.26 to 1.91)0.25 to 2.01Unclear
Tirzepatide injection
TIRZ_SC
0.74 (0.58 to 0.95)0.50 to 1.09Better
Insulin degludec
INS_DEGLUDEC
0.75 (0.51 to 1.10)0.46 to 1.22Unclear
Metformin
METFORMIN
0.76 (0.39 to 1.44)0.36 to 1.54Unclear
Insulin glargine with lixisenatide injection
IGLARLIXI_SC
0.80 (0.59 to 1.09)0.52 to 1.22Unclear
Liraglutide injection
LIRA_SC
0.81 (0.68 to 0.96)0.57 to 1.15Better
Insulin degludec with liraglutide injection
IDEGLIRA_SC
0.86 (0.61 to 1.17)0.54 to 1.29Unclear
Dulaglutide injection
DULA_SC
0.88 (0.74 to 1.04)0.61 to 1.24Unclear
Semaglutide tablet
SEMA_PO
0.90 (0.75 to 1.10)0.64 to 1.29Unclear
Additional oad
OTHER_ACTIVE_additional_OAD
0.91 (0.36 to 2.03)0.34 to 2.16Unclear
Taspoglutide injection
TASP_SC
0.91 (0.59 to 1.40)0.53 to 1.53Unclear
Exenatide injection
EXEN_SC
0.91 (0.71 to 1.16)0.61 to 1.33Unclear
Insulin glargine
INS_GLARGINE
0.91 (0.77 to 1.07)0.64 to 1.27Unclear
Standard care or no added treatment
STANDARD_CARE
0.92 (0.52 to 1.59)0.49 to 1.72Unclear
Semaglutide injection
SEMA_SC
0.92 (0.79 to 1.07)0.66 to 1.29Unclear
Efpe sc
EFPE_SC
0.92 (0.46 to 1.94)0.43 to 2.05Unclear
Sitagliptin
SITAGLIPTIN
0.93 (0.76 to 1.14)0.64 to 1.33Unclear
Insulin detemir
INS_DETEMIR
0.96 (0.29 to 3.18)0.28 to 3.30Unclear
Exenatide extended release injection
EXENER_SC
0.97 (0.78 to 1.20)0.67 to 1.41Unclear
Efsubaglutide alfa injection
EFSUBA_SC
1.00 (0.28 to 3.56)0.27 to 3.66Unclear
Exenatide extended release and dapagliflozin injection
DAPAEXEN_SC
1.00 (0.48 to 2.05)0.46 to 2.18Unclear
Albiglutide injection
ALBI_SC
1.01 (0.82 to 1.29)0.70 to 1.50Unclear
Glimepiride
GLIMEPIRIDE
1.02 (0.79 to 1.29)0.67 to 1.47Unclear
Lixisenatide injection
LIXI_SC
1.03 (0.85 to 1.27)0.72 to 1.49Unclear
Cotadutide injection
COTA_SC
1.07 (0.62 to 1.89)0.59 to 2.03Unclear
Polyethylene glycol loxenatide injection
PEGLOX_SC
1.07 (0.20 to 6.78)0.20 to 6.84Unclear
Safiglipron (HRS-7535) tablet
SAFIGL_PO
1.08 (0.54 to 2.18)0.51 to 2.31Unclear
Glibenclamide
GLIBENCLAMIDE
1.10 (0.51 to 2.37)0.48 to 2.48Unclear
Canagliflozin
CANAGLIFLOZIN
1.13 (0.57 to 2.30)0.54 to 2.42Unclear
Exenatide and rosiglitazone injection
EXENROSI_SC
1.15 (0.25 to 5.47)0.25 to 5.54Unclear
Dapagliflozin
DAPAGLIFLOZIN
1.16 (0.62 to 2.14)0.58 to 2.31Unclear
Rosiglitazone
ROSIGLITAZONE
1.18 (0.26 to 5.66)0.25 to 5.82Unclear
Orforglipron tablet
ORFO_PO
1.20 (0.90 to 1.62)0.79 to 1.82Unclear
Retatrutide injection
RETA_SC
1.27 (0.43 to 4.36)0.41 to 4.54Unclear
Insulin aspart (prandial)
INS_ASPART
1.28 (0.84 to 1.98)0.77 to 2.14Unclear
Visepegenatide injection
VISEPE_SC
1.29 (0.63 to 2.71)0.60 to 2.86Unclear
Insulin lispro (prandial)
INS_LISPRO
1.33 (0.93 to 1.91)0.84 to 2.12Unclear
Ecnoglutide injection
ECNO_SC
1.56 (0.07 to 62.96)0.06 to 62.07Unclear
Insulin icodec with semaglutide injection
ICOSEMA_SC
1.65 (0.90 to 3.09)0.83 to 3.34Unclear
Loti po
LOTI_PO
1.78 (0.60 to 6.94)0.58 to 7.15Unclear
Bofanglutide (GZR18) injection
BOFANG_SC
1.85 (0.08 to 75.80)0.08 to 76.63Unclear
Danuglipron tablet
DANU_PO
1.88 (0.43 to 14.22)0.42 to 14.79Unclear
Insulin icodec
INS_ICODEC
1.93 (0.92 to 4.20)0.88 to 4.46Unclear
Exenimp implant
EXENIMP_IMPLANT
1.96 (0.09 to 79.31)0.09 to 78.42Unclear
Pioglitazone
PIOGLITAZONE
1.98 (0.96 to 4.09)0.88 to 4.30Unclear
HRS-7535 tablet
HRS7535_PO
2.21 (0.58 to 11.77)0.57 to 12.06Unclear
Dulaglutide with macupatide injection
DULAMACU_SC
3.91 (0.14 to 153)0.14 to 153Unclear
Bgm050 sc
BGM050_SC
4.67 (0.32 to 136)0.33 to 138Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
Every treatment in a row compared with every treatment in a column
Row versus columnPLACEBOCANALIRA_SCOTHER_ACTIVE_sulfonylureaMAZD_SCECC500_POOTHER_ACTIVE_macupatideBEIN_SCEMPAGLIFLOZINLINAGLIPTININS_PREMIXOTHER_ACTIVE_investigator_choice_oral_drugOTHER_ACTIVE_basal_bolus_insulinGLP1RE_SCTIRZ_SCINS_DEGLUDECMETFORMINIGLARLIXI_SCLIRA_SCIDEGLIRA_SCDULA_SCSEMA_POOTHER_ACTIVE_additional_OADTASP_SCEXEN_SCINS_GLARGINESTANDARD_CARESEMA_SCEFPE_SCSITAGLIPTININS_DETEMIREXENER_SCEFSUBA_SCDAPAEXEN_SCALBI_SCGLIMEPIRIDELIXI_SCCOTA_SCPEGLOX_SCSAFIGL_POGLIBENCLAMIDECANAGLIFLOZINEXENROSI_SCDAPAGLIFLOZINROSIGLITAZONEORFO_PORETA_SCINS_ASPARTVISEPE_SCINS_LISPROECNO_SCICOSEMA_SCLOTI_POBOFANG_SCDANU_POINS_ICODECEXENIMP_IMPLANTPIOGLITAZONEHRS7535_PODULAMACU_SCBGM050_SC
PLACEBOPLACEBO3.83
0.13 to 270		3.01
0.64 to 18.66		2.46
0.86 to 7.90		2.22
0.03 to 215		2.10
0.05 to 211		1.96
0.03 to 170		1.83
0.02 to 180		1.67
0.02 to 161		1.55
0.95 to 2.55		1.41
0.89 to 2.22		1.40
0.67 to 3.00		1.38
0.52 to 3.85		1.36
1.05 to 1.73		1.34
0.91 to 1.95		1.32
0.70 to 2.57		1.24
0.92 to 1.70		1.23
1.04 to 1.46		1.17
0.86 to 1.63		1.14
0.96 to 1.36		1.11
0.91 to 1.33		1.10
0.49 to 2.80		1.10
0.71 to 1.69		1.10
0.86 to 1.41		1.10
0.93 to 1.30		1.09
0.63 to 1.91		1.09
0.93 to 1.27		1.08
0.52 to 2.18		1.07
0.88 to 1.31		1.04
0.31 to 3.40		1.03
0.83 to 1.28		1.00
0.28 to 3.61		1.00
0.49 to 2.07		0.99
0.78 to 1.23		0.98
0.77 to 1.27		0.97
0.79 to 1.18		0.93
0.53 to 1.60		0.93
0.15 to 4.92		0.93
0.46 to 1.84		0.91
0.42 to 1.97		0.88
0.43 to 1.77		0.87
0.18 to 4.00		0.86
0.47 to 1.60		0.84
0.18 to 3.84		0.83
0.62 to 1.11		0.79
0.23 to 2.32		0.78
0.51 to 1.19		0.77
0.37 to 1.58		0.75
0.52 to 1.07		0.64
0.02 to 15.27		0.61
0.32 to 1.11		0.56
0.14 to 1.67		0.54
0.01 to 13.07		0.53
0.07 to 2.30		0.52
0.24 to 1.09		0.51
0.01 to 11.42		0.50
0.24 to 1.05		0.45
0.08 to 1.71		0.26
0.01 to 6.94		0.21
0.01 to 3.09
CANALIRA_SC0.26
0.00 to 7.60		CANALIRA_SC0.81
0.01 to 34.72		0.65
0.01 to 22.83		0.55
0.00 to 161		0.54
0.00 to 146		0.48
0.00 to 156		0.46
0.00 to 128		0.42
0.00 to 143		0.40
0.01 to 11.97		0.37
0.01 to 10.86		0.37
0.00 to 11.09		0.36
0.00 to 12.55		0.35
0.00 to 10.57		0.35
0.01 to 10.72		0.35
0.00 to 10.88		0.33
0.00 to 9.75		0.33
0.00 to 9.40		0.31
0.00 to 9.31		0.30
0.00 to 8.71		0.29
0.00 to 8.57		0.29
0.00 to 9.88		0.29
0.00 to 8.49		0.29
0.00 to 8.73		0.29
0.00 to 8.62		0.28
0.00 to 8.56		0.29
0.00 to 8.47		0.27
0.00 to 8.88		0.28
0.00 to 8.33		0.27
0.00 to 9.74		0.27
0.00 to 8.11		0.26
0.00 to 10.32		0.26
0.00 to 8.31		0.26
0.00 to 7.92		0.26
0.00 to 7.81		0.25
0.00 to 7.44		0.24
0.00 to 7.46		0.23
0.00 to 11.11		0.24
0.00 to 7.59		0.24
0.00 to 7.73		0.23
0.00 to 7.30		0.23
0.00 to 9.11		0.22
0.00 to 7.12		0.22
0.00 to 9.05		0.22
0.00 to 6.57		0.20
0.00 to 6.98		0.21
0.00 to 6.48		0.20
0.00 to 6.19		0.20
0.00 to 5.84		0.15
0.00 to 17.37		0.16
0.00 to 4.84		0.14
0.00 to 4.71		0.13
0.00 to 14.75		0.13
0.00 to 5.67		0.14
0.00 to 4.14		0.12
0.00 to 13.92		0.13
0.00 to 4.11		0.11
0.00 to 4.51		0.06
0.00 to 7.39		0.05
0.00 to 4.47
OTHER_ACTIVE_sulfonylurea0.33
0.05 to 1.56		1.24
0.03 to 110		OTHER_ACTIVE_sulfonylurea0.82
0.10 to 5.30		0.69
0.01 to 85.02		0.69
0.01 to 85.34		0.63
0.01 to 68.71		0.58
0.01 to 71.87		0.54
0.01 to 62.27		0.51
0.08 to 2.54		0.46
0.07 to 2.26		0.45
0.06 to 2.64		0.45
0.06 to 2.79		0.45
0.07 to 2.14		0.44
0.07 to 2.16		0.43
0.06 to 2.40		0.41
0.07 to 1.97		0.41
0.07 to 1.90		0.39
0.06 to 1.85		0.38
0.06 to 1.78		0.37
0.06 to 1.72		0.36
0.05 to 2.16		0.36
0.06 to 1.81		0.36
0.06 to 1.72		0.36
0.06 to 1.69		0.36
0.05 to 1.86		0.36
0.06 to 1.72		0.35
0.05 to 1.95		0.36
0.06 to 1.69		0.34
0.04 to 2.47		0.34
0.05 to 1.63		0.32
0.04 to 2.48		0.33
0.05 to 1.81		0.33
0.05 to 1.55		0.33
0.05 to 1.53		0.32
0.05 to 1.51		0.30
0.05 to 1.64		0.30
0.02 to 3.08		0.30
0.04 to 1.67		0.30
0.04 to 1.64		0.29
0.04 to 1.61		0.28
0.03 to 2.50		0.28
0.04 to 1.52		0.27
0.03 to 2.36		0.27
0.04 to 1.31		0.25
0.03 to 1.60		0.26
0.04 to 1.25		0.25
0.04 to 1.39		0.25
0.04 to 1.21		0.21
0.00 to 6.85		0.20
0.03 to 1.05		0.18
0.02 to 1.30		0.17
0.00 to 6.11		0.17
0.01 to 1.41		0.17
0.02 to 0.96		0.16
0.00 to 5.44		0.17
0.02 to 0.95		0.14
0.01 to 1.14		0.08
0.00 to 3.11		0.07
0.00 to 1.62
MAZD_SC0.41
0.13 to 1.16		1.54
0.04 to 123		1.22
0.19 to 9.83		MAZD_SC0.89
0.01 to 95.39		0.86
0.02 to 97.31		0.78
0.01 to 74.69		0.73
0.01 to 81.85		0.68
0.01 to 72.40		0.63
0.17 to 1.99		0.57
0.17 to 1.81		0.57
0.14 to 2.11		0.56
0.12 to 2.44		0.55
0.17 to 1.64		0.55
0.16 to 1.66		0.54
0.14 to 1.94		0.50
0.15 to 1.48		0.50
0.16 to 1.46		0.47
0.14 to 1.44		0.46
0.15 to 1.34		0.45
0.14 to 1.30		0.45
0.11 to 1.79		0.44
0.13 to 1.40		0.45
0.14 to 1.31		0.45
0.14 to 1.29		0.44
0.12 to 1.48		0.44
0.13 to 1.30		0.43
0.11 to 1.59		0.44
0.13 to 1.28		0.42
0.08 to 2.10		0.42
0.13 to 1.23		0.40
0.07 to 2.10		0.40
0.10 to 1.45		0.40
0.12 to 1.18		0.40
0.12 to 1.16		0.39
0.12 to 1.14		0.38
0.10 to 1.25		0.37
0.04 to 2.69		0.37
0.10 to 1.37		0.37
0.09 to 1.36		0.36
0.09 to 1.26		0.35
0.05 to 2.19		0.35
0.09 to 1.21		0.34
0.05 to 2.15		0.34
0.10 to 1.02		0.31
0.06 to 1.48		0.31
0.09 to 1.00		0.31
0.08 to 1.14		0.31
0.09 to 0.93		0.26
0.01 to 7.18		0.25
0.06 to 0.84		0.22
0.04 to 1.01		0.21
0.00 to 6.00		0.21
0.02 to 1.35		0.21
0.05 to 0.76		0.20
0.00 to 5.48		0.20
0.05 to 0.75		0.18
0.02 to 1.00		0.10
0.00 to 3.17		0.08
0.00 to 1.49
ECC500_PO0.45
0.00 to 34.23		1.83
0.01 to 753		1.45
0.01 to 146		1.13
0.01 to 97.88		ECC500_PO0.99
0.00 to 491		0.88
0.00 to 436		0.87
0.00 to 494		0.77
0.00 to 385		0.69
0.01 to 55.09		0.64
0.01 to 48.42		0.64
0.01 to 51.08		0.63
0.01 to 55.19		0.61
0.01 to 45.84		0.60
0.01 to 45.69		0.59
0.01 to 48.77		0.56
0.01 to 42.16		0.55
0.01 to 42.21		0.52
0.01 to 40.16		0.51
0.01 to 38.94		0.50
0.01 to 37.18		0.50
0.00 to 43.06		0.49
0.00 to 39.50		0.49
0.01 to 36.90		0.49
0.00 to 37.15		0.49
0.00 to 38.25		0.49
0.01 to 36.84		0.48
0.00 to 38.44		0.48
0.01 to 36.60		0.47
0.00 to 40.90		0.46
0.00 to 34.85		0.44
0.00 to 40.31		0.45
0.00 to 33.86		0.44
0.00 to 34.40		0.44
0.00 to 33.18		0.43
0.00 to 33.56		0.41
0.00 to 33.58		0.40
0.00 to 43.80		0.41
0.00 to 33.75		0.41
0.00 to 33.62		0.39
0.00 to 31.40		0.38
0.00 to 39.25		0.39
0.00 to 30.82		0.37
0.00 to 40.25		0.38
0.00 to 28.17		0.34
0.00 to 29.26		0.35
0.00 to 27.22		0.34
0.00 to 28.55		0.34
0.00 to 26.24		0.28
0.00 to 60.74		0.27
0.00 to 21.35		0.24
0.00 to 20.12		0.23
0.00 to 63.89		0.22
0.00 to 24.68		0.24
0.00 to 19.21		0.21
0.00 to 49.62		0.23
0.00 to 18.86		0.19
0.00 to 20.27		0.11
0.00 to 23.91		0.09
0.00 to 15.68
OTHER_ACTIVE_macupatide0.48
0.00 to 21.07		1.86
0.01 to 510		1.44
0.01 to 99.14		1.17
0.01 to 61.58		1.01
0.00 to 290		OTHER_ACTIVE_macupatide0.87
0.00 to 355		0.81
0.00 to 417		0.77
0.00 to 337		0.72
0.01 to 34.65		0.67
0.01 to 30.68		0.65
0.01 to 33.10		0.65
0.01 to 34.46		0.63
0.01 to 29.01		0.63
0.01 to 29.23		0.61
0.01 to 30.15		0.59
0.01 to 26.29		0.59
0.01 to 26.20		0.55
0.01 to 25.42		0.55
0.01 to 24.28		0.52
0.01 to 23.21		0.51
0.01 to 27.21		0.52
0.01 to 24.40		0.52
0.01 to 23.76		0.52
0.01 to 23.27		0.52
0.01 to 24.69		0.51
0.01 to 22.99		0.50
0.00 to 25.01		0.51
0.01 to 23.07		0.49
0.00 to 26.89		0.49
0.00 to 21.27		0.46
0.00 to 26.58		0.47
0.00 to 23.21		0.47
0.00 to 21.06		0.47
0.00 to 20.45		0.46
0.00 to 21.16		0.43
0.00 to 20.53		0.42
0.00 to 26.48		0.43
0.00 to 21.62		0.43
0.00 to 21.35		0.41
0.00 to 20.21		0.40
0.00 to 26.43		0.40
0.00 to 19.13		0.38
0.00 to 23.96		0.39
0.00 to 17.48		0.36
0.00 to 19.03		0.36
0.00 to 16.72		0.36
0.00 to 16.56		0.35
0.00 to 15.97		0.27
0.00 to 45.55		0.28
0.00 to 13.84		0.25
0.00 to 14.16		0.23
0.00 to 35.46		0.23
0.00 to 14.53		0.24
0.00 to 13.26		0.21
0.00 to 37.20		0.23
0.00 to 11.80		0.20
0.00 to 12.15		0.12
0.00 to 8.88		0.09
0.00 to 11.14
BEIN_SC0.51
0.01 to 33.28		2.07
0.01 to 779		1.58
0.01 to 143		1.28
0.01 to 101		1.14
0.00 to 485		1.15
0.00 to 489		BEIN_SC0.95
0.00 to 475		0.87
0.00 to 401		0.79
0.01 to 53.90		0.73
0.01 to 47.28		0.73
0.01 to 48.78		0.72
0.01 to 51.08		0.70
0.01 to 46.03		0.69
0.01 to 46.33		0.67
0.01 to 46.57		0.64
0.01 to 42.35		0.63
0.01 to 41.87		0.60
0.01 to 40.99		0.58
0.01 to 39.25		0.56
0.01 to 36.57		0.57
0.01 to 40.11		0.56
0.01 to 36.93		0.57
0.01 to 36.13		0.56
0.01 to 36.95		0.56
0.01 to 38.07		0.56
0.01 to 36.89		0.55
0.01 to 39.06		0.55
0.01 to 36.25		0.53
0.01 to 43.44		0.52
0.01 to 34.18		0.51
0.00 to 43.19		0.50
0.01 to 35.17		0.51
0.01 to 33.11		0.50
0.01 to 33.63		0.49
0.01 to 32.14		0.48
0.01 to 33.02		0.46
0.00 to 45.32		0.46
0.01 to 32.60		0.45
0.01 to 33.99		0.45
0.00 to 30.34		0.44
0.00 to 38.82		0.44
0.00 to 30.58		0.44
0.00 to 34.78		0.43
0.00 to 27.84		0.39
0.00 to 32.66		0.39
0.00 to 26.95		0.39
0.00 to 27.68		0.39
0.00 to 25.48		0.30
0.00 to 59.30		0.31
0.00 to 22.49		0.28
0.00 to 21.94		0.25
0.00 to 58.78		0.25
0.00 to 25.46		0.26
0.00 to 19.86		0.24
0.00 to 48.02		0.26
0.00 to 17.27		0.22
0.00 to 19.06		0.12
0.00 to 27.98		0.10
0.00 to 16.25
EMPAGLIFLOZIN0.55
0.01 to 43.89		2.17
0.01 to 765		1.71
0.01 to 183		1.37
0.01 to 124		1.15
0.00 to 657		1.23
0.00 to 688		1.05
0.00 to 589		EMPAGLIFLOZIN0.95
0.00 to 520		0.85
0.01 to 68.32		0.77
0.01 to 61.58		0.77
0.01 to 64.44		0.75
0.01 to 65.52		0.75
0.01 to 55.69		0.74
0.01 to 57.88		0.73
0.01 to 62.67		0.68
0.01 to 53.60		0.68
0.01 to 51.51		0.64
0.01 to 50.67		0.62
0.01 to 47.77		0.61
0.01 to 47.24		0.60
0.01 to 49.71		0.61
0.01 to 49.41		0.60
0.01 to 46.41		0.60
0.01 to 46.89		0.59
0.01 to 50.98		0.60
0.01 to 46.55		0.60
0.01 to 46.63		0.59
0.01 to 46.33		0.56
0.01 to 50.71		0.56
0.01 to 45.05		0.54
0.00 to 53.68		0.55
0.01 to 48.04		0.55
0.01 to 41.61		0.53
0.01 to 43.04		0.53
0.01 to 41.46		0.51
0.00 to 41.10		0.49
0.00 to 59.45		0.50
0.01 to 42.57		0.49
0.00 to 41.38		0.49
0.00 to 39.18		0.47
0.00 to 48.63		0.47
0.00 to 40.92		0.44
0.00 to 47.03		0.45
0.00 to 36.14		0.42
0.00 to 40.87		0.43
0.00 to 32.95		0.42
0.00 to 33.47		0.41
0.00 to 31.31		0.33
0.00 to 69.00		0.33
0.00 to 27.54		0.29
0.00 to 28.81		0.27
0.00 to 60.73		0.28
0.00 to 28.43		0.28
0.00 to 23.27		0.26
0.00 to 56.40		0.28
0.00 to 24.02		0.23
0.00 to 22.71		0.13
0.00 to 37.86		0.11
0.00 to 19.40
LINAGLIPTIN0.60
0.01 to 46.03		2.38
0.01 to 957		1.87
0.02 to 190		1.48
0.01 to 135		1.30
0.00 to 737		1.30
0.00 to 588		1.15
0.00 to 520		1.05
0.00 to 630		LINAGLIPTIN0.90
0.01 to 74.49		0.85
0.01 to 67.10		0.83
0.01 to 73.18		0.81
0.01 to 68.60		0.81
0.01 to 63.95		0.79
0.01 to 62.01		0.77
0.01 to 61.67		0.74
0.01 to 57.88		0.73
0.01 to 58.06		0.70
0.01 to 54.56		0.68
0.01 to 52.96		0.66
0.01 to 51.48		0.65
0.01 to 59.15		0.65
0.01 to 52.24		0.65
0.01 to 50.99		0.65
0.01 to 51.72		0.66
0.01 to 54.27		0.65
0.01 to 50.44		0.64
0.01 to 50.72		0.64
0.01 to 50.98		0.63
0.01 to 55.28		0.62
0.01 to 47.76		0.61
0.01 to 52.51		0.59
0.01 to 47.98		0.59
0.01 to 45.64		0.59
0.01 to 45.69		0.57
0.01 to 45.46		0.56
0.01 to 46.34		0.53
0.00 to 56.63		0.55
0.01 to 43.13		0.54
0.01 to 47.49		0.52
0.01 to 45.34		0.51
0.00 to 53.04		0.51
0.01 to 40.40		0.49
0.00 to 55.89		0.50
0.01 to 38.83		0.47
0.00 to 42.20		0.47
0.00 to 36.39		0.45
0.00 to 37.62		0.45
0.00 to 34.16		0.35
0.00 to 73.98		0.36
0.00 to 29.29		0.32
0.00 to 26.86		0.29
0.00 to 65.57		0.29
0.00 to 31.46		0.31
0.00 to 25.62		0.28
0.00 to 65.18		0.30
0.00 to 23.49		0.26
0.00 to 26.14		0.15
0.00 to 33.65		0.12
0.00 to 22.47
INS_PREMIX0.65
0.39 to 1.05		2.48
0.08 to 177		1.95
0.39 to 12.38		1.58
0.50 to 5.76		1.44
0.02 to 138		1.38
0.03 to 138		1.26
0.02 to 116		1.17
0.01 to 123		1.11
0.01 to 106		INS_PREMIX0.91
0.47 to 1.76		0.90
0.38 to 2.21		0.89
0.30 to 2.67		0.87
0.50 to 1.49		0.86
0.47 to 1.56		0.85
0.38 to 1.97		0.80
0.48 to 1.33		0.80
0.48 to 1.31		0.76
0.43 to 1.33		0.74
0.44 to 1.21		0.71
0.42 to 1.19		0.71
0.27 to 1.96		0.71
0.39 to 1.28		0.71
0.44 to 1.12		0.71
0.43 to 1.14		0.70
0.34 to 1.47		0.70
0.42 to 1.16		0.69
0.28 to 1.64		0.69
0.41 to 1.13		0.67
0.18 to 2.46		0.66
0.39 to 1.11		0.65
0.17 to 2.57		0.65
0.27 to 1.52		0.64
0.37 to 1.09		0.63
0.38 to 1.04		0.62
0.37 to 1.04		0.60
0.29 to 1.25		0.59
0.09 to 3.47		0.60
0.25 to 1.37		0.59
0.24 to 1.41		0.57
0.24 to 1.30		0.56
0.11 to 2.73		0.56
0.25 to 1.22		0.54
0.11 to 2.64		0.54
0.30 to 0.94		0.51
0.13 to 1.69		0.50
0.27 to 0.95		0.50
0.20 to 1.17		0.49
0.27 to 0.84		0.41
0.01 to 9.86		0.39
0.18 to 0.85		0.36
0.09 to 1.20		0.35
0.01 to 8.58		0.34
0.04 to 1.61		0.33
0.14 to 0.79		0.33
0.01 to 7.60		0.33
0.14 to 0.73		0.29
0.05 to 1.21		0.17
0.00 to 4.58		0.14
0.00 to 2.04
OTHER_ACTIVE_investigator_choice_oral_drug0.71
0.45 to 1.13		2.73
0.09 to 194		2.15
0.44 to 13.44		1.75
0.55 to 6.00		1.57
0.02 to 161		1.49
0.03 to 149		1.38
0.02 to 132		1.30
0.02 to 133		1.18
0.01 to 118		1.10
0.57 to 2.14		OTHER_ACTIVE_investigator_choice_oral_drug0.99
0.42 to 2.39		0.98
0.34 to 2.97		0.96
0.58 to 1.61		0.95
0.54 to 1.71		0.93
0.43 to 2.09		0.88
0.52 to 1.54		0.87
0.57 to 1.34		0.83
0.49 to 1.46		0.81
0.51 to 1.31		0.79
0.49 to 1.28		0.78
0.31 to 2.18		0.78
0.43 to 1.45		0.78
0.48 to 1.31		0.78
0.49 to 1.25		0.77
0.39 to 1.57		0.77
0.48 to 1.24		0.77
0.32 to 1.77		0.76
0.48 to 1.25		0.75
0.21 to 2.61		0.73
0.45 to 1.21		0.71
0.18 to 2.79		0.71
0.30 to 1.67		0.70
0.42 to 1.15		0.69
0.43 to 1.16		0.68
0.42 to 1.13		0.66
0.32 to 1.34		0.66
0.10 to 3.75		0.66
0.28 to 1.52		0.64
0.27 to 1.52		0.63
0.27 to 1.43		0.62
0.12 to 2.95		0.61
0.28 to 1.32		0.60
0.12 to 2.91		0.59
0.34 to 1.00		0.56
0.15 to 1.81		0.55
0.30 to 1.01		0.55
0.23 to 1.26		0.54
0.30 to 0.95		0.46
0.01 to 10.92		0.43
0.20 to 0.92		0.40
0.10 to 1.29		0.38
0.01 to 9.79		0.38
0.05 to 1.77		0.37
0.15 to 0.89		0.36
0.01 to 8.81		0.36
0.15 to 0.85		0.32
0.06 to 1.33		0.18
0.00 to 5.00		0.15
0.01 to 2.23
OTHER_ACTIVE_basal_bolus_insulin0.71
0.33 to 1.49		2.71
0.09 to 209		2.21
0.38 to 15.68		1.77
0.47 to 6.90		1.57
0.02 to 168		1.55
0.03 to 162		1.37
0.02 to 132		1.30
0.02 to 132		1.21
0.01 to 123		1.11
0.45 to 2.66		1.01
0.42 to 2.39		OTHER_ACTIVE_basal_bolus_insulin0.99
0.29 to 3.39		0.96
0.44 to 2.06		0.96
0.42 to 2.09		0.94
0.35 to 2.52		0.88
0.40 to 1.97		0.88
0.41 to 1.87		0.84
0.40 to 1.72		0.81
0.38 to 1.74		0.79
0.36 to 1.70		0.79
0.27 to 2.46		0.79
0.34 to 1.84		0.79
0.36 to 1.70		0.78
0.37 to 1.65		0.78
0.30 to 1.97		0.78
0.36 to 1.62		0.77
0.27 to 2.13		0.77
0.36 to 1.65		0.75
0.18 to 2.99		0.73
0.33 to 1.57		0.72
0.16 to 3.17		0.71
0.24 to 2.00		0.71
0.32 to 1.54		0.70
0.32 to 1.49		0.69
0.31 to 1.46		0.66
0.27 to 1.63		0.66
0.09 to 4.15		0.66
0.24 to 1.80		0.65
0.23 to 1.85		0.63
0.23 to 1.71		0.62
0.11 to 3.32		0.62
0.24 to 1.61		0.60
0.11 to 3.25		0.59
0.27 to 1.29		0.56
0.13 to 2.10		0.56
0.23 to 1.31		0.55
0.19 to 1.55		0.54
0.24 to 1.22		0.45
0.01 to 12.20		0.43
0.16 to 1.11		0.40
0.09 to 1.54		0.38
0.01 to 9.96		0.37
0.04 to 2.05		0.37
0.13 to 1.05		0.36
0.01 to 8.92		0.36
0.13 to 1.00		0.32
0.06 to 1.52		0.18
0.00 to 5.39		0.15
0.00 to 2.45
GLP1RE_SC0.72
0.26 to 1.91		2.76
0.08 to 214		2.21
0.36 to 17.86		1.78
0.41 to 8.20		1.58
0.02 to 170		1.53
0.03 to 158		1.38
0.02 to 139		1.34
0.02 to 142		1.23
0.01 to 126		1.12
0.38 to 3.29		1.02
0.34 to 2.96		1.01
0.30 to 3.42		GLP1RE_SC0.97
0.35 to 2.65		0.97
0.33 to 2.78		0.95
0.28 to 3.16		0.90
0.34 to 2.29		0.89
0.32 to 2.38		0.84
0.29 to 2.35		0.82
0.30 to 2.22		0.80
0.29 to 2.15		0.80
0.22 to 3.04		0.79
0.27 to 2.31		0.79
0.29 to 2.20		0.79
0.29 to 2.13		0.78
0.25 to 2.39		0.78
0.29 to 2.11		0.77
0.23 to 2.55		0.78
0.28 to 2.12		0.75
0.16 to 3.51		0.74
0.26 to 2.08		0.72
0.14 to 3.61		0.72
0.21 to 2.42		0.71
0.25 to 1.94		0.71
0.25 to 1.94		0.69
0.25 to 1.88		0.67
0.22 to 2.07		0.67
0.08 to 4.71		0.66
0.19 to 2.20		0.65
0.19 to 2.25		0.64
0.19 to 2.06		0.63
0.10 to 3.70		0.62
0.19 to 1.99		0.61
0.10 to 3.67		0.60
0.21 to 1.68		0.57
0.12 to 2.41		0.57
0.19 to 1.64		0.55
0.16 to 1.90		0.54
0.19 to 1.53		0.46
0.01 to 12.12		0.44
0.14 to 1.37		0.40
0.08 to 1.76		0.38
0.01 to 10.78		0.38
0.04 to 2.31		0.37
0.11 to 1.27		0.36
0.01 to 10.35		0.36
0.11 to 1.29		0.32
0.05 to 1.71		0.18
0.00 to 5.70		0.15
0.00 to 2.68
TIRZ_SC0.74
0.58 to 0.95		2.82
0.09 to 201		2.24
0.47 to 14.15		1.82
0.61 to 6.02		1.65
0.02 to 155		1.58
0.03 to 159		1.44
0.02 to 128		1.34
0.02 to 136		1.24
0.02 to 121		1.14
0.67 to 1.98		1.04
0.62 to 1.73		1.04
0.49 to 2.27		1.03
0.38 to 2.85		TIRZ_SC0.99
0.68 to 1.44		0.97
0.49 to 1.98		0.92
0.64 to 1.33		0.91
0.69 to 1.19		0.86
0.61 to 1.24		0.84
0.65 to 1.10		0.82
0.61 to 1.10		0.81
0.35 to 2.08		0.81
0.50 to 1.33		0.81
0.59 to 1.13		0.81
0.65 to 1.02		0.81
0.44 to 1.47		0.80
0.61 to 1.06		0.80
0.37 to 1.68		0.79
0.59 to 1.07		0.77
0.23 to 2.59		0.76
0.55 to 1.05		0.74
0.20 to 2.74		0.74
0.34 to 1.61		0.73
0.53 to 0.98		0.72
0.53 to 1.00		0.71
0.52 to 0.97		0.69
0.37 to 1.24		0.69
0.11 to 3.70		0.69
0.32 to 1.41		0.67
0.30 to 1.49		0.65
0.31 to 1.36		0.64
0.13 to 3.00		0.64
0.32 to 1.24		0.62
0.13 to 2.99		0.61
0.42 to 0.90		0.58
0.16 to 1.76		0.58
0.35 to 0.94		0.57
0.26 to 1.20		0.56
0.39 to 0.78		0.47
0.01 to 11.46		0.45
0.23 to 0.85		0.42
0.11 to 1.27		0.40
0.01 to 9.45		0.39
0.05 to 1.72		0.38
0.17 to 0.83		0.37
0.01 to 8.41		0.37
0.18 to 0.80		0.34
0.06 to 1.32		0.19
0.00 to 5.24		0.16
0.01 to 2.25
INS_DEGLUDEC0.75
0.51 to 1.10		2.87
0.09 to 198		2.28
0.46 to 13.69		1.83
0.60 to 6.35		1.68
0.02 to 163		1.59
0.03 to 157		1.46
0.02 to 132		1.36
0.02 to 143		1.27
0.02 to 121		1.16
0.64 to 2.14		1.05
0.58 to 1.86		1.04
0.48 to 2.37		1.03
0.36 to 2.99		1.01
0.69 to 1.47		INS_DEGLUDEC0.98
0.47 to 2.13		0.93
0.58 to 1.48		0.92
0.63 to 1.36		0.88
0.61 to 1.27		0.85
0.58 to 1.27		0.83
0.54 to 1.26		0.82
0.34 to 2.20		0.82
0.47 to 1.43		0.82
0.54 to 1.28		0.82
0.56 to 1.20		0.81
0.41 to 1.61		0.81
0.55 to 1.22		0.81
0.35 to 1.78		0.80
0.53 to 1.21		0.78
0.22 to 2.72		0.77
0.50 to 1.19		0.74
0.20 to 2.84		0.74
0.33 to 1.69		0.74
0.48 to 1.13		0.73
0.48 to 1.14		0.72
0.48 to 1.11		0.69
0.36 to 1.36		0.69
0.11 to 3.79		0.69
0.30 to 1.51		0.68
0.29 to 1.55		0.66
0.30 to 1.46		0.65
0.13 to 3.10		0.65
0.31 to 1.33		0.63
0.13 to 3.00		0.62
0.38 to 1.01		0.59
0.16 to 1.84		0.58
0.33 to 1.02		0.57
0.25 to 1.31		0.56
0.34 to 0.91		0.48
0.01 to 11.81		0.45
0.22 to 0.92		0.42
0.10 to 1.32		0.40
0.01 to 9.84		0.40
0.05 to 1.84		0.39
0.17 to 0.90		0.38
0.01 to 8.69		0.38
0.17 to 0.86		0.34
0.06 to 1.38		0.19
0.00 to 5.12		0.16
0.01 to 2.31
METFORMIN0.76
0.39 to 1.44		2.89
0.09 to 203		2.31
0.42 to 15.69		1.86
0.52 to 6.93		1.69
0.02 to 167		1.64
0.03 to 163		1.49
0.02 to 142		1.37
0.02 to 150		1.30
0.02 to 136		1.18
0.51 to 2.64		1.07
0.48 to 2.34		1.06
0.40 to 2.88		1.05
0.32 to 3.54		1.03
0.50 to 2.03		1.02
0.47 to 2.15		METFORMIN0.94
0.46 to 1.90		0.93
0.47 to 1.82		0.89
0.43 to 1.83		0.87
0.45 to 1.61		0.84
0.42 to 1.64		0.83
0.30 to 2.60		0.83
0.38 to 1.79		0.83
0.42 to 1.64		0.83
0.42 to 1.60		0.83
0.34 to 1.94		0.83
0.42 to 1.58		0.82
0.30 to 2.11		0.82
0.41 to 1.60		0.79
0.20 to 3.10		0.78
0.39 to 1.54		0.76
0.18 to 3.14		0.76
0.28 to 1.99		0.75
0.37 to 1.49		0.74
0.37 to 1.48		0.73
0.36 to 1.44		0.70
0.30 to 1.63		0.71
0.11 to 3.68		0.70
0.26 to 1.82		0.69
0.25 to 1.89		0.67
0.26 to 1.73		0.66
0.12 to 3.46		0.65
0.26 to 1.60		0.63
0.12 to 3.31		0.63
0.30 to 1.28		0.60
0.15 to 2.11		0.59
0.27 to 1.26		0.58
0.22 to 1.54		0.57
0.27 to 1.18		0.48
0.01 to 12.83		0.46
0.19 to 1.12		0.42
0.09 to 1.55		0.40
0.01 to 10.47		0.40
0.05 to 2.04		0.39
0.14 to 1.05		0.38
0.01 to 9.15		0.39
0.14 to 1.02		0.34
0.06 to 1.49		0.20
0.00 to 5.29		0.16
0.01 to 2.59
IGLARLIXI_SC0.80
0.59 to 1.09		3.05
0.10 to 218		2.44
0.51 to 15.30		1.99
0.68 to 6.67		1.80
0.02 to 172		1.70
0.04 to 161		1.56
0.02 to 141		1.47
0.02 to 149		1.36
0.02 to 129		1.25
0.75 to 2.09		1.14
0.65 to 1.91		1.13
0.51 to 2.48		1.11
0.44 to 2.91		1.09
0.75 to 1.56		1.07
0.68 to 1.72		1.06
0.53 to 2.18		IGLARLIXI_SC0.99
0.71 to 1.37		0.94
0.63 to 1.42		0.92
0.66 to 1.27		0.89
0.61 to 1.26		0.88
0.37 to 2.33		0.88
0.53 to 1.47		0.88
0.62 to 1.26		0.88
0.66 to 1.17		0.88
0.47 to 1.63		0.88
0.63 to 1.21		0.87
0.38 to 1.85		0.87
0.61 to 1.21		0.84
0.24 to 2.81		0.83
0.57 to 1.18		0.81
0.22 to 2.97		0.80
0.36 to 1.78		0.80
0.55 to 1.15		0.79
0.55 to 1.14		0.78
0.56 to 1.08		0.75
0.40 to 1.39		0.75
0.12 to 4.06		0.75
0.34 to 1.59		0.73
0.32 to 1.64		0.71
0.33 to 1.50		0.70
0.14 to 3.25		0.69
0.34 to 1.37		0.68
0.14 to 3.17		0.67
0.43 to 1.02		0.63
0.18 to 1.93		0.63
0.37 to 1.05		0.62
0.27 to 1.35		0.60
0.39 to 0.94		0.52
0.01 to 12.83		0.49
0.24 to 0.95		0.45
0.11 to 1.40		0.43
0.01 to 10.80		0.42
0.05 to 1.91		0.42
0.18 to 0.92		0.41
0.01 to 9.18		0.41
0.19 to 0.88		0.36
0.07 to 1.41		0.21
0.01 to 5.53		0.17
0.01 to 2.47
LIRA_SC0.81
0.68 to 0.96		3.07
0.11 to 222		2.44
0.53 to 15.02		1.99
0.69 to 6.41		1.80
0.02 to 173		1.70
0.04 to 173		1.58
0.02 to 140		1.47
0.02 to 146		1.37
0.02 to 131		1.26
0.76 to 2.09		1.15
0.74 to 1.74		1.14
0.53 to 2.43		1.13
0.42 to 3.13		1.10
0.84 to 1.44		1.09
0.73 to 1.60		1.07
0.55 to 2.12		1.01
0.73 to 1.41		LIRA_SC0.95
0.70 to 1.33		0.92
0.75 to 1.14		0.90
0.71 to 1.13		0.89
0.40 to 2.23		0.89
0.57 to 1.39		0.89
0.68 to 1.18		0.89
0.73 to 1.08		0.89
0.51 to 1.56		0.88
0.72 to 1.08		0.88
0.41 to 1.82		0.87
0.71 to 1.08		0.84
0.25 to 2.80		0.83
0.65 to 1.09		0.81
0.22 to 2.97		0.81
0.38 to 1.71		0.81
0.61 to 1.04		0.79
0.63 to 1.03		0.79
0.60 to 1.01		0.76
0.42 to 1.31		0.76
0.12 to 4.04		0.75
0.36 to 1.51		0.73
0.35 to 1.56		0.72
0.35 to 1.46		0.71
0.15 to 3.19		0.70
0.37 to 1.33		0.68
0.14 to 3.18		0.68
0.48 to 0.93		0.64
0.18 to 1.88		0.63
0.41 to 0.97		0.63
0.29 to 1.30		0.61
0.42 to 0.88		0.52
0.01 to 12.43		0.49
0.26 to 0.91		0.46
0.12 to 1.37		0.44
0.01 to 10.62		0.43
0.06 to 1.88		0.42
0.19 to 0.89		0.42
0.01 to 9.62		0.41
0.20 to 0.86		0.37
0.07 to 1.38		0.21
0.01 to 5.50		0.17
0.01 to 2.48
IDEGLIRA_SC0.86
0.61 to 1.17		3.21
0.11 to 228		2.58
0.54 to 16.19		2.11
0.70 to 7.08		1.91
0.02 to 185		1.81
0.04 to 180		1.67
0.02 to 152		1.56
0.02 to 160		1.42
0.02 to 137		1.32
0.75 to 2.33		1.20
0.68 to 2.03		1.20
0.58 to 2.52		1.19
0.43 to 3.41		1.16
0.81 to 1.63		1.14
0.79 to 1.65		1.13
0.55 to 2.33		1.06
0.70 to 1.59		1.06
0.75 to 1.44		IDEGLIRA_SC0.97
0.69 to 1.35		0.95
0.65 to 1.35		0.94
0.40 to 2.42		0.93
0.57 to 1.56		0.94
0.64 to 1.35		0.94
0.68 to 1.25		0.93
0.50 to 1.72		0.93
0.65 to 1.29		0.93
0.40 to 2.00		0.92
0.64 to 1.28		0.88
0.26 to 3.01		0.88
0.60 to 1.26		0.85
0.23 to 3.21		0.85
0.38 to 1.85		0.85
0.56 to 1.22		0.84
0.57 to 1.20		0.83
0.57 to 1.18		0.80
0.42 to 1.49		0.80
0.12 to 4.40		0.79
0.37 to 1.67		0.78
0.35 to 1.75		0.75
0.35 to 1.58		0.75
0.15 to 3.46		0.74
0.37 to 1.45		0.71
0.15 to 3.35		0.71
0.46 to 1.08		0.67
0.18 to 2.08		0.67
0.39 to 1.11		0.66
0.29 to 1.44		0.64
0.40 to 1.00		0.54
0.01 to 12.86		0.52
0.26 to 1.01		0.48
0.12 to 1.49		0.46
0.01 to 11.14		0.45
0.06 to 2.09		0.44
0.19 to 0.98		0.43
0.01 to 10.17		0.43
0.20 to 0.94		0.39
0.07 to 1.50		0.22
0.01 to 5.84		0.18
0.01 to 2.69
DULA_SC0.88
0.74 to 1.04		3.35
0.11 to 232		2.66
0.56 to 16.36		2.16
0.75 to 6.90		1.97
0.03 to 189		1.83
0.04 to 184		1.74
0.03 to 152		1.61
0.02 to 157		1.48
0.02 to 138		1.36
0.83 to 2.27		1.24
0.77 to 1.97		1.23
0.58 to 2.65		1.22
0.45 to 3.38		1.19
0.91 to 1.54		1.18
0.79 to 1.73		1.16
0.62 to 2.21		1.09
0.79 to 1.51		1.08
0.87 to 1.33		1.03
0.74 to 1.45		DULA_SC0.97
0.75 to 1.24		0.96
0.43 to 2.46		0.97
0.61 to 1.51		0.96
0.74 to 1.26		0.96
0.81 to 1.15		0.96
0.54 to 1.69		0.96
0.77 to 1.17		0.95
0.44 to 1.94		0.95
0.74 to 1.19		0.91
0.28 to 3.00		0.90
0.70 to 1.17		0.88
0.24 to 3.23		0.88
0.42 to 1.85		0.87
0.65 to 1.13		0.86
0.66 to 1.13		0.85
0.65 to 1.09		0.81
0.46 to 1.43		0.82
0.13 to 4.34		0.82
0.40 to 1.66		0.80
0.37 to 1.73		0.77
0.38 to 1.57		0.77
0.16 to 3.46		0.76
0.40 to 1.43		0.74
0.16 to 3.45		0.73
0.52 to 1.02		0.69
0.20 to 2.05		0.69
0.43 to 1.07		0.67
0.32 to 1.40		0.66
0.45 to 0.96		0.56
0.01 to 13.31		0.53
0.28 to 0.99		0.49
0.13 to 1.48		0.48
0.01 to 11.46		0.46
0.06 to 2.05		0.45
0.21 to 0.97		0.45
0.01 to 10.22		0.44
0.21 to 0.93		0.40
0.07 to 1.53		0.22
0.01 to 6.08		0.19
0.01 to 2.71
SEMA_PO0.90
0.75 to 1.10		3.46
0.12 to 237		2.73
0.58 to 16.83		2.23
0.77 to 7.23		2.02
0.03 to 191		1.91
0.04 to 194		1.77
0.03 to 155		1.64
0.02 to 161		1.52
0.02 to 145		1.40
0.84 to 2.38		1.27
0.78 to 2.05		1.27
0.59 to 2.78		1.26
0.46 to 3.47		1.22
0.91 to 1.65		1.21
0.79 to 1.85		1.19
0.61 to 2.38		1.12
0.80 to 1.63		1.11
0.89 to 1.41		1.06
0.74 to 1.55		1.03
0.81 to 1.33		SEMA_PO1.00
0.44 to 2.50		0.99
0.63 to 1.58		0.99
0.74 to 1.35		0.99
0.79 to 1.27		0.98
0.55 to 1.77		0.98
0.78 to 1.24		0.98
0.44 to 2.04		0.97
0.77 to 1.23		0.94
0.28 to 3.14		0.93
0.71 to 1.24		0.91
0.25 to 3.36		0.90
0.43 to 1.90		0.90
0.67 to 1.18		0.88
0.67 to 1.21		0.87
0.67 to 1.15		0.84
0.47 to 1.49		0.84
0.13 to 4.47		0.84
0.40 to 1.69		0.82
0.38 to 1.79		0.80
0.38 to 1.63		0.79
0.17 to 3.61		0.78
0.41 to 1.49		0.76
0.16 to 3.53		0.75
0.55 to 1.03		0.71
0.20 to 2.16		0.71
0.44 to 1.11		0.70
0.33 to 1.46		0.68
0.45 to 1.02		0.58
0.01 to 13.84		0.55
0.29 to 1.03		0.51
0.13 to 1.53		0.49
0.01 to 11.75		0.48
0.06 to 2.08		0.47
0.21 to 1.00		0.46
0.01 to 10.51		0.46
0.22 to 0.98		0.41
0.08 to 1.56		0.23
0.01 to 6.34		0.19
0.01 to 2.81
OTHER_ACTIVE_additional_OAD0.91
0.36 to 2.03		3.45
0.10 to 258		2.76
0.46 to 20.45		2.25
0.56 to 9.34		1.99
0.02 to 206		1.96
0.04 to 197		1.75
0.02 to 173		1.68
0.02 to 182		1.53
0.02 to 156		1.41
0.51 to 3.64		1.28
0.46 to 3.23		1.27
0.41 to 3.74		1.24
0.33 to 4.60		1.23
0.48 to 2.84		1.23
0.46 to 2.93		1.21
0.38 to 3.38		1.13
0.43 to 2.67		1.12
0.45 to 2.52		1.07
0.41 to 2.52		1.04
0.41 to 2.35		1.00
0.40 to 2.30		OTHER_ACTIVE_additional_OAD0.99
0.36 to 2.51		1.00
0.39 to 2.28		1.00
0.39 to 2.25		1.00
0.35 to 2.59		0.99
0.40 to 2.16		0.98
0.31 to 2.93		0.98
0.39 to 2.23		0.94
0.22 to 3.87		0.94
0.36 to 2.15		0.91
0.18 to 4.20		0.91
0.28 to 2.70		0.90
0.35 to 2.07		0.89
0.35 to 2.06		0.88
0.35 to 1.99		0.83
0.30 to 2.27		0.83
0.11 to 5.25		0.84
0.27 to 2.41		0.81
0.25 to 2.51		0.80
0.26 to 2.27		0.79
0.13 to 4.38		0.78
0.26 to 2.09		0.76
0.13 to 4.17		0.76
0.29 to 1.78		0.71
0.16 to 2.87		0.71
0.26 to 1.74		0.70
0.21 to 2.12		0.68
0.26 to 1.65		0.58
0.01 to 15.47		0.55
0.18 to 1.47		0.50
0.10 to 2.09		0.48
0.01 to 12.97		0.47
0.05 to 2.68		0.47
0.14 to 1.39		0.45
0.01 to 11.75		0.46
0.15 to 1.36		0.40
0.06 to 2.01		0.24
0.01 to 6.92		0.19
0.01 to 3.12
TASP_SC0.91
0.59 to 1.40		3.44
0.12 to 250		2.75
0.55 to 17.56		2.25
0.71 to 7.91		2.03
0.03 to 209		1.92
0.04 to 188		1.80
0.03 to 162		1.65
0.02 to 175		1.53
0.02 to 156		1.41
0.78 to 2.57		1.28
0.69 to 2.33		1.27
0.54 to 2.97		1.26
0.43 to 3.77		1.23
0.75 to 1.98		1.22
0.70 to 2.12		1.20
0.56 to 2.63		1.14
0.68 to 1.88		1.12
0.72 to 1.75		1.07
0.64 to 1.76		1.04
0.66 to 1.63		1.01
0.63 to 1.59		1.01
0.40 to 2.76		TASP_SC1.00
0.67 to 1.51		1.00
0.64 to 1.55		0.99
0.50 to 1.99		0.99
0.63 to 1.56		0.98
0.40 to 2.27		0.98
0.64 to 1.51		0.95
0.27 to 3.29		0.94
0.58 to 1.51		0.92
0.24 to 3.52		0.91
0.39 to 2.12		0.90
0.55 to 1.45		0.89
0.57 to 1.42		0.88
0.56 to 1.38		0.85
0.42 to 1.69		0.84
0.12 to 4.94		0.85
0.37 to 1.89		0.83
0.35 to 1.96		0.80
0.35 to 1.83		0.79
0.16 to 3.74		0.79
0.37 to 1.65		0.76
0.15 to 3.52		0.76
0.45 to 1.27		0.72
0.19 to 2.26		0.71
0.39 to 1.28		0.70
0.29 to 1.65		0.68
0.40 to 1.16		0.58
0.01 to 13.42		0.55
0.26 to 1.14		0.51
0.12 to 1.68		0.49
0.01 to 11.58		0.48
0.06 to 2.27		0.47
0.20 to 1.10		0.47
0.01 to 10.89		0.46
0.20 to 1.04		0.41
0.07 to 1.66		0.23
0.01 to 6.27		0.19
0.01 to 2.89
EXEN_SC0.91
0.71 to 1.16		3.50
0.11 to 247		2.76
0.58 to 17.23		2.24
0.77 to 7.30		2.04
0.03 to 189		1.92
0.04 to 194		1.76
0.03 to 159		1.66
0.02 to 174		1.53
0.02 to 146		1.41
0.90 to 2.26		1.29
0.77 to 2.09		1.27
0.59 to 2.76		1.27
0.45 to 3.47		1.23
0.89 to 1.69		1.22
0.78 to 1.87		1.21
0.61 to 2.40		1.13
0.79 to 1.62		1.12
0.85 to 1.48		1.07
0.74 to 1.56		1.04
0.79 to 1.35		1.01
0.74 to 1.36		1.00
0.44 to 2.60		1.00
0.66 to 1.49		EXEN_SC1.00
0.78 to 1.29		0.99
0.55 to 1.80		0.99
0.75 to 1.30		0.98
0.45 to 2.08		0.98
0.73 to 1.30		0.96
0.28 to 3.14		0.94
0.69 to 1.27		0.92
0.26 to 3.38		0.91
0.42 to 1.96		0.91
0.64 to 1.23		0.90
0.67 to 1.18		0.88
0.66 to 1.18		0.85
0.46 to 1.54		0.85
0.13 to 4.64		0.85
0.40 to 1.74		0.82
0.37 to 1.83		0.80
0.37 to 1.67		0.79
0.17 to 3.58		0.79
0.41 to 1.50		0.76
0.16 to 3.50		0.76
0.51 to 1.11		0.72
0.20 to 2.23		0.72
0.43 to 1.14		0.70
0.32 to 1.49		0.69
0.46 to 1.00		0.58
0.01 to 14.07		0.55
0.28 to 1.05		0.51
0.13 to 1.57		0.49
0.01 to 11.90		0.48
0.06 to 2.16		0.47
0.21 to 1.02		0.47
0.01 to 10.42		0.46
0.22 to 0.96		0.41
0.08 to 1.59		0.23
0.01 to 6.17		0.19
0.01 to 2.82
INS_GLARGINE0.91
0.77 to 1.07		3.48
0.12 to 247		2.74
0.59 to 16.94		2.24
0.77 to 7.26		2.03
0.03 to 200		1.91
0.04 to 196		1.79
0.03 to 157		1.66
0.02 to 165		1.53
0.02 to 146		1.41
0.88 to 2.33		1.29
0.80 to 2.02		1.28
0.61 to 2.72		1.27
0.47 to 3.41		1.23
0.98 to 1.55		1.22
0.83 to 1.78		1.20
0.63 to 2.36		1.13
0.86 to 1.51		1.12
0.92 to 1.37		1.07
0.80 to 1.47		1.04
0.87 to 1.24		1.01
0.79 to 1.27		1.00
0.44 to 2.54		1.00
0.65 to 1.55		1.00
0.77 to 1.29		INS_GLARGINE1.00
0.57 to 1.75		0.99
0.81 to 1.20		0.99
0.46 to 2.02		0.98
0.79 to 1.21		0.95
0.28 to 3.09		0.94
0.73 to 1.20		0.91
0.25 to 3.32		0.91
0.44 to 1.92		0.91
0.69 to 1.15		0.89
0.70 to 1.15		0.88
0.69 to 1.11		0.85
0.47 to 1.48		0.85
0.13 to 4.52		0.85
0.41 to 1.69		0.83
0.39 to 1.80		0.80
0.39 to 1.63		0.80
0.16 to 3.63		0.79
0.41 to 1.47		0.77
0.16 to 3.53		0.76
0.54 to 1.05		0.72
0.21 to 2.12		0.72
0.45 to 1.09		0.70
0.33 to 1.45		0.69
0.48 to 0.98		0.59
0.01 to 14.03		0.55
0.29 to 1.02		0.52
0.13 to 1.54		0.49
0.01 to 11.86		0.48
0.06 to 2.11		0.47
0.21 to 1.00		0.46
0.01 to 10.59		0.46
0.22 to 0.97		0.41
0.08 to 1.59		0.23
0.01 to 6.27		0.20
0.01 to 2.74
STANDARD_CARE0.92
0.52 to 1.59		3.51
0.12 to 243		2.77
0.54 to 18.64		2.28
0.68 to 8.33		2.04
0.03 to 202		1.91
0.04 to 189		1.80
0.03 to 166		1.71
0.02 to 181		1.52
0.02 to 155		1.43
0.68 to 2.95		1.29
0.64 to 2.59		1.28
0.51 to 3.35		1.28
0.42 to 4.00		1.24
0.68 to 2.25		1.23
0.62 to 2.41		1.21
0.51 to 2.92		1.14
0.61 to 2.14		1.13
0.64 to 1.98		1.07
0.58 to 2.01		1.04
0.59 to 1.85		1.02
0.57 to 1.83		1.00
0.39 to 2.88		1.01
0.50 to 2.00		1.01
0.55 to 1.83		1.00
0.57 to 1.75		STANDARD_CARE1.00
0.59 to 1.70		0.99
0.39 to 2.41		0.99
0.56 to 1.74		0.96
0.26 to 3.40		0.95
0.52 to 1.69		0.92
0.23 to 3.78		0.92
0.37 to 2.26		0.91
0.50 to 1.64		0.90
0.50 to 1.63		0.89
0.49 to 1.57		0.85
0.39 to 1.86		0.84
0.12 to 4.78		0.86
0.35 to 2.01		0.83
0.32 to 2.14		0.81
0.33 to 1.92		0.81
0.15 to 3.97		0.79
0.35 to 1.78		0.78
0.15 to 4.03		0.76
0.40 to 1.42		0.73
0.18 to 2.46		0.72
0.36 to 1.41		0.71
0.27 to 1.75		0.69
0.35 to 1.31		0.58
0.01 to 14.63		0.55
0.25 to 1.22		0.52
0.12 to 1.75		0.50
0.01 to 12.83		0.48
0.06 to 2.36		0.47
0.19 to 1.15		0.47
0.01 to 11.08		0.47
0.19 to 1.15		0.41
0.07 to 1.71		0.23
0.01 to 6.48		0.20
0.01 to 2.89
SEMA_SC0.92
0.79 to 1.07		3.51
0.12 to 249		2.77
0.58 to 17.22		2.28
0.77 to 7.41		2.05
0.03 to 196		1.95
0.04 to 193		1.78
0.03 to 162		1.67
0.02 to 166		1.55
0.02 to 149		1.42
0.86 to 2.38		1.29
0.81 to 2.06		1.29
0.62 to 2.76		1.28
0.47 to 3.47		1.25
0.94 to 1.64		1.23
0.82 to 1.83		1.21
0.63 to 2.38		1.14
0.83 to 1.59		1.13
0.93 to 1.39		1.07
0.78 to 1.53		1.05
0.86 to 1.29		1.02
0.80 to 1.28		1.01
0.46 to 2.49		1.01
0.64 to 1.58		1.01
0.77 to 1.34		1.01
0.83 to 1.24		1.00
0.59 to 1.71		SEMA_SC1.00
0.47 to 2.02		0.99
0.80 to 1.24		0.96
0.29 to 3.15		0.95
0.74 to 1.22		0.93
0.25 to 3.38		0.92
0.44 to 1.92		0.91
0.69 to 1.18		0.90
0.69 to 1.20		0.89
0.69 to 1.14		0.86
0.48 to 1.50		0.86
0.14 to 4.60		0.85
0.41 to 1.72		0.83
0.39 to 1.84		0.81
0.41 to 1.59		0.81
0.17 to 3.66		0.79
0.42 to 1.50		0.77
0.16 to 3.62		0.77
0.55 to 1.06		0.73
0.21 to 2.15		0.72
0.47 to 1.08		0.71
0.33 to 1.45		0.69
0.47 to 1.01		0.58
0.01 to 13.82		0.56
0.30 to 1.01		0.52
0.13 to 1.56		0.50
0.01 to 12.11		0.49
0.06 to 2.11		0.48
0.22 to 0.99		0.47
0.01 to 10.89		0.47
0.22 to 0.97		0.41
0.08 to 1.57		0.24
0.01 to 6.36		0.20
0.01 to 2.75
EFPE_SC0.92
0.46 to 1.94		3.64
0.11 to 269		2.83
0.51 to 20.19		2.31
0.63 to 9.16		2.08
0.03 to 206		2.00
0.04 to 213		1.81
0.03 to 174		1.68
0.02 to 184		1.56
0.02 to 159		1.44
0.61 to 3.51		1.30
0.56 to 3.15		1.30
0.47 to 3.76		1.29
0.39 to 4.36		1.26
0.59 to 2.70		1.23
0.56 to 2.86		1.22
0.47 to 3.31		1.15
0.54 to 2.61		1.14
0.55 to 2.45		1.08
0.50 to 2.49		1.05
0.51 to 2.26		1.02
0.49 to 2.25		1.02
0.34 to 3.26		1.02
0.44 to 2.47		1.02
0.48 to 2.23		1.01
0.50 to 2.19		1.01
0.42 to 2.57		1.00
0.49 to 2.13		EFPE_SC0.99
0.48 to 2.15		0.97
0.24 to 4.00		0.95
0.46 to 2.09		0.93
0.21 to 4.01		0.93
0.34 to 2.65		0.91
0.44 to 1.98		0.91
0.43 to 1.99		0.89
0.43 to 1.95		0.86
0.35 to 2.15		0.86
0.12 to 5.42		0.86
0.31 to 2.39		0.84
0.30 to 2.43		0.82
0.30 to 2.25		0.82
0.14 to 4.39		0.80
0.32 to 2.08		0.78
0.14 to 4.34		0.77
0.37 to 1.68		0.73
0.18 to 2.79		0.73
0.32 to 1.68		0.72
0.25 to 1.97		0.70
0.32 to 1.58		0.60
0.01 to 14.74		0.56
0.22 to 1.46		0.52
0.12 to 1.94		0.50
0.01 to 13.10		0.48
0.06 to 2.59		0.48
0.17 to 1.34		0.46
0.01 to 11.33		0.47
0.17 to 1.29		0.41
0.07 to 1.90		0.24
0.01 to 6.47		0.20
0.01 to 3.14
SITAGLIPTIN0.93
0.76 to 1.14		3.55
0.12 to 243		2.79
0.59 to 17.44		2.28
0.78 to 7.50		2.08
0.03 to 200		1.97
0.04 to 196		1.81
0.03 to 163		1.68
0.02 to 165		1.56
0.02 to 149		1.44
0.89 to 2.43		1.31
0.80 to 2.08		1.30
0.61 to 2.80		1.29
0.47 to 3.58		1.26
0.93 to 1.69		1.25
0.83 to 1.88		1.23
0.62 to 2.46		1.16
0.83 to 1.63		1.15
0.93 to 1.40		1.09
0.78 to 1.55		1.06
0.84 to 1.35		1.03
0.81 to 1.29		1.02
0.45 to 2.58		1.02
0.66 to 1.57		1.02
0.77 to 1.36		1.02
0.83 to 1.27		1.01
0.57 to 1.79		1.01
0.81 to 1.25		1.01
0.47 to 2.07		SITAGLIPTIN0.97
0.29 to 3.19		0.96
0.73 to 1.26		0.93
0.25 to 3.45		0.93
0.44 to 1.98		0.93
0.68 to 1.22		0.91
0.71 to 1.19		0.90
0.68 to 1.18		0.87
0.48 to 1.53		0.87
0.14 to 4.73		0.86
0.42 to 1.75		0.84
0.39 to 1.83		0.82
0.39 to 1.69		0.81
0.17 to 3.71		0.80
0.42 to 1.53		0.78
0.16 to 3.63		0.77
0.55 to 1.07		0.73
0.21 to 2.21		0.73
0.46 to 1.14		0.72
0.33 to 1.50		0.70
0.47 to 1.03		0.60
0.01 to 14.62		0.57
0.29 to 1.05		0.53
0.13 to 1.57		0.50
0.01 to 12.17		0.49
0.06 to 2.16		0.48
0.22 to 1.03		0.47
0.01 to 10.94		0.47
0.23 to 0.98		0.42
0.08 to 1.59		0.24
0.01 to 6.35		0.20
0.01 to 2.87
INS_DETEMIR0.96
0.29 to 3.18		3.67
0.10 to 297		2.97
0.41 to 24.50		2.38
0.48 to 12.37		2.12
0.02 to 244		2.06
0.04 to 238		1.89
0.02 to 194		1.79
0.02 to 193		1.59
0.02 to 183		1.50
0.41 to 5.47		1.34
0.38 to 4.77		1.34
0.33 to 5.68		1.34
0.28 to 6.32		1.30
0.39 to 4.34		1.28
0.37 to 4.54		1.26
0.32 to 4.96		1.19
0.36 to 4.11		1.19
0.36 to 3.95		1.13
0.33 to 3.88		1.10
0.33 to 3.63		1.07
0.32 to 3.54		1.07
0.26 to 4.61		1.06
0.30 to 3.72		1.05
0.32 to 3.59		1.06
0.32 to 3.55		1.04
0.29 to 3.90		1.05
0.32 to 3.46		1.04
0.25 to 4.10		1.03
0.31 to 3.47		INS_DETEMIR0.99
0.31 to 3.22		0.96
0.16 to 5.51		0.96
0.24 to 3.79		0.95
0.28 to 3.26		0.94
0.29 to 3.13		0.93
0.28 to 3.09		0.89
0.24 to 3.33		0.88
0.10 to 6.76		0.89
0.23 to 3.51		0.87
0.21 to 3.62		0.84
0.21 to 3.39		0.83
0.12 to 5.72		0.83
0.22 to 3.10		0.81
0.11 to 5.54		0.80
0.24 to 2.72		0.76
0.13 to 3.68		0.75
0.21 to 2.65		0.74
0.18 to 3.07		0.72
0.21 to 2.49		0.62
0.01 to 16.55		0.58
0.15 to 2.26		0.53
0.09 to 2.71		0.52
0.01 to 14.84		0.49
0.05 to 3.50		0.49
0.12 to 1.99		0.49
0.01 to 14.38		0.49
0.12 to 1.89		0.43
0.05 to 2.63		0.24
0.01 to 7.85		0.20
0.01 to 3.67
EXENER_SC0.97
0.78 to 1.20		3.68
0.12 to 258		2.93
0.61 to 18.29		2.40
0.81 to 7.79		2.17
0.03 to 213		2.04
0.05 to 208		1.94
0.03 to 167		1.77
0.02 to 183		1.63
0.02 to 154		1.51
0.90 to 2.56		1.37
0.83 to 2.21		1.36
0.64 to 3.00		1.35
0.48 to 3.78		1.31
0.96 to 1.81		1.30
0.84 to 1.99		1.28
0.65 to 2.58		1.21
0.85 to 1.74		1.20
0.92 to 1.54		1.13
0.79 to 1.67		1.11
0.85 to 1.43		1.08
0.81 to 1.41		1.07
0.47 to 2.74		1.07
0.66 to 1.73		1.06
0.79 to 1.45		1.06
0.83 to 1.37		1.06
0.59 to 1.91		1.06
0.82 to 1.35		1.05
0.48 to 2.18		1.05
0.79 to 1.37		1.01
0.31 to 3.28		EXENER_SC0.98
0.27 to 3.59		0.97
0.48 to 1.95		0.97
0.70 to 1.29		0.95
0.71 to 1.29		0.94
0.70 to 1.25		0.91
0.50 to 1.61		0.91
0.14 to 4.77		0.90
0.44 to 1.80		0.88
0.40 to 1.92		0.85
0.41 to 1.73		0.85
0.17 to 3.85		0.84
0.45 to 1.52		0.82
0.17 to 3.81		0.81
0.56 to 1.16		0.77
0.22 to 2.31		0.76
0.47 to 1.20		0.75
0.34 to 1.58		0.73
0.49 to 1.09		0.62
0.02 to 15.45		0.59
0.30 to 1.11		0.54
0.14 to 1.66		0.52
0.01 to 12.74		0.51
0.07 to 2.27		0.50
0.22 to 1.09		0.49
0.01 to 11.51		0.49
0.24 to 1.02		0.44
0.08 to 1.68		0.25
0.01 to 6.61		0.21
0.01 to 2.89
EFSUBA_SC1.00
0.28 to 3.56		3.83
0.10 to 336		3.12
0.40 to 27.85		2.47
0.48 to 13.96		2.29
0.02 to 250		2.19
0.04 to 249		1.96
0.02 to 203		1.86
0.02 to 219		1.65
0.02 to 192		1.54
0.39 to 6.02		1.40
0.36 to 5.44		1.39
0.32 to 6.20		1.38
0.28 to 7.28		1.35
0.37 to 4.95		1.35
0.35 to 4.98		1.31
0.32 to 5.66		1.23
0.34 to 4.59		1.23
0.34 to 4.45		1.17
0.31 to 4.36		1.13
0.31 to 4.09		1.10
0.30 to 4.00		1.10
0.24 to 5.41		1.09
0.28 to 4.18		1.09
0.30 to 3.90		1.09
0.30 to 3.98		1.09
0.26 to 4.33		1.08
0.30 to 3.92		1.07
0.25 to 4.77		1.07
0.29 to 3.94		1.05
0.18 to 6.07		1.03
0.28 to 3.76		EFSUBA_SC1.00
0.23 to 4.25		0.98
0.27 to 3.57		0.98
0.27 to 3.53		0.96
0.27 to 3.44		0.93
0.23 to 3.67		0.92
0.10 to 7.52		0.93
0.21 to 4.04		0.91
0.21 to 4.05		0.88
0.20 to 3.74		0.88
0.11 to 6.39		0.86
0.21 to 3.53		0.84
0.12 to 6.20		0.83
0.22 to 3.07		0.79
0.13 to 4.38		0.77
0.20 to 3.02		0.77
0.17 to 3.26		0.75
0.20 to 2.78		0.64
0.01 to 20.02		0.60
0.15 to 2.47		0.55
0.09 to 3.15		0.54
0.01 to 16.89		0.51
0.05 to 3.84		0.52
0.12 to 2.20		0.50
0.01 to 14.16		0.51
0.12 to 2.30		0.44
0.06 to 2.97		0.25
0.01 to 8.72		0.20
0.01 to 4.22
DAPAEXEN_SC1.00
0.48 to 2.05		3.79
0.12 to 302		3.06
0.55 to 21.83		2.48
0.69 to 9.89		2.23
0.03 to 224		2.14
0.04 to 223		1.99
0.03 to 180		1.83
0.02 to 196		1.69
0.02 to 171		1.55
0.66 to 3.74		1.42
0.60 to 3.30		1.40
0.50 to 4.10		1.39
0.41 to 4.77		1.35
0.62 to 2.90		1.34
0.59 to 3.00		1.32
0.50 to 3.53		1.24
0.56 to 2.74		1.23
0.59 to 2.61		1.17
0.54 to 2.64		1.14
0.54 to 2.40		1.11
0.53 to 2.31		1.10
0.37 to 3.58		1.10
0.47 to 2.56		1.09
0.51 to 2.37		1.10
0.52 to 2.29		1.09
0.44 to 2.73		1.09
0.52 to 2.27		1.08
0.38 to 2.97		1.07
0.51 to 2.26		1.04
0.26 to 4.09		1.03
0.51 to 2.10		1.00
0.24 to 4.39		DAPAEXEN_SC1.00
0.46 to 2.08		0.98
0.45 to 2.11		0.96
0.45 to 2.06		0.93
0.37 to 2.32		0.92
0.13 to 5.61		0.93
0.40 to 2.14		0.91
0.32 to 2.66		0.88
0.33 to 2.40		0.87
0.16 to 4.64		0.86
0.43 to 1.74		0.85
0.15 to 4.51		0.83
0.38 to 1.79		0.78
0.18 to 2.95		0.78
0.34 to 1.80		0.77
0.27 to 2.17		0.75
0.33 to 1.68		0.65
0.02 to 16.75		0.61
0.23 to 1.54		0.56
0.12 to 2.14		0.54
0.01 to 13.91		0.53
0.06 to 2.78		0.52
0.19 to 1.43		0.52
0.01 to 12.47		0.50
0.19 to 1.39		0.45
0.07 to 2.05		0.25
0.01 to 7.43		0.21
0.01 to 3.41
ALBI_SC1.01
0.82 to 1.29		3.88
0.13 to 279		3.05
0.65 to 19.32		2.49
0.85 to 8.21		2.27
0.03 to 213		2.12
0.05 to 220		1.98
0.03 to 178		1.83
0.02 to 184		1.68
0.02 to 161		1.57
0.92 to 2.70		1.42
0.87 to 2.39		1.41
0.65 to 3.15		1.40
0.52 to 3.94		1.36
1.02 to 1.87		1.35
0.88 to 2.10		1.33
0.67 to 2.74		1.25
0.87 to 1.83		1.24
0.96 to 1.65		1.18
0.82 to 1.77		1.15
0.89 to 1.53		1.11
0.85 to 1.50		1.11
0.48 to 2.89		1.11
0.69 to 1.83		1.10
0.81 to 1.57		1.10
0.87 to 1.45		1.10
0.61 to 2.01		1.10
0.85 to 1.45		1.10
0.50 to 2.29		1.08
0.82 to 1.48		1.05
0.31 to 3.57		1.03
0.78 to 1.44		1.02
0.28 to 3.71		1.00
0.48 to 2.17		ALBI_SC0.98
0.73 to 1.41		0.97
0.72 to 1.33		0.94
0.52 to 1.72		0.94
0.15 to 5.14		0.94
0.45 to 1.93		0.91
0.42 to 2.05		0.89
0.42 to 1.86		0.88
0.18 to 4.00		0.87
0.46 to 1.70		0.85
0.18 to 3.98		0.84
0.59 to 1.23		0.80
0.23 to 2.44		0.79
0.49 to 1.27		0.78
0.35 to 1.64		0.76
0.52 to 1.11		0.65
0.02 to 15.35		0.61
0.31 to 1.17		0.57
0.14 to 1.73		0.54
0.01 to 12.78		0.54
0.07 to 2.36		0.53
0.24 to 1.14		0.52
0.01 to 11.79		0.51
0.24 to 1.08		0.46
0.09 to 1.77		0.26
0.01 to 7.02		0.22
0.01 to 3.01
GLIMEPIRIDE1.02
0.79 to 1.29		3.85
0.13 to 270		3.08
0.66 to 19.10		2.52
0.86 to 8.35		2.27
0.03 to 223		2.15
0.05 to 213		1.99
0.03 to 173		1.87
0.02 to 182		1.71
0.02 to 165		1.58
0.96 to 2.64		1.45
0.86 to 2.33		1.43
0.67 to 3.09		1.42
0.52 to 3.92		1.38
1.00 to 1.88		1.37
0.88 to 2.07		1.35
0.68 to 2.72		1.27
0.88 to 1.81		1.26
0.97 to 1.59		1.20
0.83 to 1.74		1.17
0.88 to 1.50		1.13
0.83 to 1.50		1.13
0.49 to 2.85		1.12
0.71 to 1.77		1.12
0.85 to 1.50		1.12
0.87 to 1.43		1.12
0.61 to 2.00		1.11
0.83 to 1.44		1.10
0.50 to 2.30		1.10
0.84 to 1.41		1.06
0.32 to 3.48		1.05
0.77 to 1.41		1.02
0.28 to 3.74		1.02
0.47 to 2.20		1.02
0.71 to 1.38		GLIMEPIRIDE0.99
0.72 to 1.33		0.95
0.52 to 1.70		0.94
0.15 to 5.06		0.95
0.45 to 1.92		0.92
0.43 to 2.02		0.90
0.42 to 1.85		0.89
0.18 to 4.16		0.88
0.45 to 1.71		0.85
0.18 to 4.00		0.85
0.57 to 1.24		0.81
0.23 to 2.44		0.80
0.49 to 1.26		0.79
0.35 to 1.68		0.77
0.50 to 1.13		0.66
0.02 to 15.58		0.62
0.31 to 1.17		0.57
0.14 to 1.76		0.55
0.01 to 13.28		0.54
0.07 to 2.41		0.53
0.23 to 1.14		0.52
0.01 to 11.86		0.52
0.24 to 1.10		0.46
0.09 to 1.78		0.26
0.01 to 7.06		0.22
0.01 to 3.18
LIXI_SC1.03
0.85 to 1.27		3.97
0.13 to 279		3.14
0.66 to 19.58		2.56
0.87 to 8.49		2.31
0.03 to 225		2.19
0.05 to 221		2.03
0.03 to 177		1.89
0.02 to 182		1.74
0.02 to 165		1.61
0.96 to 2.70		1.46
0.89 to 2.40		1.45
0.69 to 3.20		1.45
0.53 to 3.98		1.40
1.03 to 1.92		1.39
0.90 to 2.10		1.37
0.69 to 2.76		1.29
0.93 to 1.79		1.27
0.99 to 1.66		1.21
0.85 to 1.77		1.18
0.92 to 1.53		1.14
0.87 to 1.50		1.14
0.50 to 2.88		1.14
0.72 to 1.80		1.14
0.85 to 1.53		1.13
0.90 to 1.46		1.13
0.64 to 2.06		1.12
0.88 to 1.45		1.12
0.51 to 2.33		1.11
0.85 to 1.47		1.08
0.32 to 3.55		1.06
0.80 to 1.43		1.04
0.29 to 3.75		1.04
0.48 to 2.22		1.03
0.75 to 1.38		1.01
0.75 to 1.38		LIXI_SC0.97
0.53 to 1.71		0.97
0.15 to 5.27		0.96
0.46 to 1.97		0.94
0.43 to 2.08		0.92
0.44 to 1.88		0.91
0.19 to 4.13		0.89
0.47 to 1.69		0.87
0.18 to 4.04		0.86
0.61 to 1.23		0.82
0.23 to 2.45		0.81
0.51 to 1.28		0.80
0.37 to 1.69		0.78
0.52 to 1.16		0.66
0.02 to 15.63		0.63
0.32 to 1.19		0.58
0.15 to 1.78		0.55
0.01 to 13.57		0.55
0.07 to 2.40		0.54
0.24 to 1.15		0.53
0.01 to 12.00		0.53
0.25 to 1.11		0.47
0.09 to 1.82		0.26
0.01 to 7.14		0.22
0.01 to 3.12
COTA_SC1.07
0.62 to 1.89		4.12
0.13 to 298		3.30
0.61 to 22.20		2.65
0.80 to 9.65		2.43
0.03 to 225		2.33
0.05 to 233		2.08
0.03 to 197		1.96
0.02 to 207		1.79
0.02 to 180		1.65
0.80 to 3.45		1.51
0.75 to 3.11		1.51
0.61 to 3.77		1.50
0.48 to 4.56		1.46
0.80 to 2.67		1.44
0.74 to 2.82		1.42
0.61 to 3.34		1.34
0.72 to 2.52		1.32
0.76 to 2.36		1.26
0.67 to 2.38		1.23
0.70 to 2.17		1.19
0.67 to 2.14		1.20
0.44 to 3.37		1.18
0.59 to 2.38		1.18
0.65 to 2.18		1.18
0.68 to 2.11		1.17
0.54 to 2.56		1.16
0.67 to 2.08		1.16
0.46 to 2.86		1.16
0.65 to 2.09		1.13
0.30 to 4.10		1.10
0.62 to 2.02		1.08
0.27 to 4.28		1.07
0.43 to 2.69		1.06
0.58 to 1.93		1.05
0.59 to 1.94		1.04
0.58 to 1.89		COTA_SC0.99
0.14 to 5.80		1.00
0.40 to 2.44		0.97
0.38 to 2.55		0.94
0.39 to 2.40		0.93
0.18 to 4.67		0.93
0.40 to 2.19		0.90
0.17 to 4.54		0.90
0.48 to 1.68		0.84
0.22 to 2.95		0.84
0.42 to 1.68		0.83
0.33 to 2.08		0.81
0.42 to 1.55		0.70
0.02 to 17.49		0.65
0.29 to 1.46		0.60
0.14 to 2.10		0.58
0.01 to 14.62		0.56
0.07 to 2.80		0.56
0.22 to 1.38		0.55
0.01 to 13.47		0.55
0.22 to 1.36		0.49
0.08 to 2.05		0.28
0.01 to 7.74		0.23
0.01 to 3.55
PEGLOX_SC1.07
0.20 to 6.78		4.36
0.09 to 419		3.39
0.32 to 42.37		2.73
0.37 to 22.97		2.51
0.02 to 310		2.40
0.04 to 300		2.16
0.02 to 253		2.04
0.02 to 281		1.87
0.02 to 224		1.69
0.29 to 11.13		1.52
0.27 to 10.09		1.51
0.24 to 11.45		1.50
0.21 to 12.22		1.46
0.27 to 9.35		1.45
0.26 to 9.23		1.41
0.27 to 9.51		1.33
0.25 to 8.51		1.32
0.25 to 8.31		1.25
0.23 to 8.24		1.23
0.23 to 7.81		1.19
0.22 to 7.57		1.20
0.19 to 8.85		1.19
0.20 to 8.12		1.18
0.22 to 7.57		1.18
0.22 to 7.61		1.19
0.21 to 8.20		1.16
0.22 to 7.24		1.16
0.18 to 8.46		1.16
0.21 to 7.35		1.13
0.15 to 10.10		1.10
0.21 to 7.08		1.09
0.13 to 10.05		1.09
0.18 to 7.42		1.07
0.19 to 6.75		1.06
0.20 to 6.64		1.03
0.19 to 6.67		1.01
0.17 to 6.93		PEGLOX_SC1.00
0.16 to 6.90		0.98
0.15 to 7.24		0.95
0.15 to 6.99		0.94
0.10 to 10.27		0.93
0.16 to 6.10		0.92
0.09 to 9.58		0.90
0.16 to 5.76		0.85
0.11 to 7.48		0.85
0.15 to 5.45		0.83
0.14 to 6.20		0.81
0.15 to 5.23		0.68
0.01 to 27.32		0.66
0.11 to 4.60		0.60
0.07 to 5.31		0.58
0.01 to 22.46		0.57
0.04 to 6.38		0.56
0.09 to 4.22		0.55
0.01 to 21.55		0.56
0.09 to 3.90		0.48
0.05 to 4.82		0.28
0.00 to 12.51		0.23
0.01 to 5.65
SAFIGL_PO1.08
0.54 to 2.18		4.13
0.13 to 306		3.31
0.60 to 23.37		2.67
0.73 to 10.03		2.43
0.03 to 239		2.33
0.05 to 240		2.15
0.03 to 191		1.99
0.02 to 194		1.83
0.02 to 192		1.67
0.73 to 3.96		1.52
0.66 to 3.58		1.51
0.56 to 4.22		1.51
0.46 to 5.22		1.45
0.71 to 3.09		1.44
0.66 to 3.31		1.42
0.55 to 3.82		1.34
0.63 to 2.95		1.33
0.66 to 2.76		1.26
0.60 to 2.73		1.22
0.60 to 2.53		1.19
0.59 to 2.49		1.19
0.41 to 3.75		1.18
0.53 to 2.70		1.18
0.57 to 2.49		1.18
0.59 to 2.42		1.17
0.50 to 2.90		1.17
0.58 to 2.42		1.17
0.42 to 3.20		1.16
0.57 to 2.40		1.12
0.29 to 4.37		1.11
0.56 to 2.27		1.08
0.25 to 4.74		1.08
0.47 to 2.52		1.07
0.52 to 2.23		1.05
0.52 to 2.24		1.04
0.51 to 2.15		1.00
0.41 to 2.50		1.00
0.14 to 6.13		SAFIGL_PO0.97
0.36 to 2.80		0.95
0.36 to 2.51		0.94
0.17 to 4.95		0.93
0.54 to 1.64		0.91
0.16 to 4.85		0.90
0.43 to 1.91		0.85
0.20 to 3.16		0.84
0.38 to 1.96		0.82
0.31 to 2.33		0.81
0.37 to 1.79		0.70
0.02 to 17.07		0.65
0.25 to 1.65		0.60
0.13 to 2.34		0.58
0.01 to 14.41		0.56
0.07 to 2.94		0.56
0.20 to 1.56		0.54
0.01 to 13.56		0.54
0.20 to 1.50		0.48
0.08 to 2.23		0.27
0.01 to 7.62		0.23
0.01 to 3.64
GLIBENCLAMIDE1.10
0.51 to 2.37		4.18
0.13 to 303		3.38
0.61 to 23.53		2.71
0.73 to 11.27		2.43
0.03 to 258		2.33
0.05 to 235		2.21
0.03 to 194		2.02
0.02 to 215		1.86
0.02 to 198		1.70
0.71 to 4.21		1.56
0.66 to 3.64		1.54
0.54 to 4.38		1.53
0.44 to 5.34		1.49
0.67 to 3.29		1.47
0.65 to 3.40		1.46
0.53 to 4.07		1.37
0.61 to 3.08		1.36
0.64 to 2.84		1.29
0.57 to 2.90		1.25
0.58 to 2.71		1.22
0.56 to 2.64		1.23
0.40 to 3.97		1.21
0.51 to 2.87		1.21
0.55 to 2.68		1.21
0.55 to 2.59		1.20
0.47 to 3.13		1.20
0.54 to 2.54		1.19
0.41 to 3.28		1.19
0.55 to 2.56		1.14
0.28 to 4.76		1.14
0.52 to 2.48		1.10
0.25 to 4.71		1.10
0.38 to 3.13		1.10
0.49 to 2.36		1.08
0.50 to 2.33		1.07
0.48 to 2.32		1.04
0.39 to 2.62		1.02
0.14 to 6.47		1.03
0.36 to 2.79		GLIBENCLAMIDE0.97
0.34 to 2.73		0.96
0.17 to 5.34		0.95
0.35 to 2.53		0.92
0.17 to 4.96		0.92
0.40 to 2.06		0.86
0.20 to 3.31		0.86
0.36 to 2.04		0.84
0.29 to 2.40		0.83
0.35 to 1.90		0.70
0.02 to 17.85		0.67
0.25 to 1.74		0.61
0.13 to 2.35		0.59
0.01 to 16.37		0.58
0.07 to 3.02		0.57
0.20 to 1.59		0.57
0.01 to 14.09		0.56
0.20 to 1.58		0.49
0.08 to 2.30		0.28
0.01 to 8.16		0.24
0.01 to 3.66
CANAGLIFLOZIN1.13
0.57 to 2.30		4.31
0.14 to 315		3.46
0.62 to 24.19		2.80
0.79 to 11.05		2.54
0.03 to 255		2.46
0.05 to 254		2.23
0.03 to 205		2.05
0.03 to 216		1.93
0.02 to 189		1.76
0.77 to 4.17		1.59
0.70 to 3.69		1.59
0.58 to 4.41		1.57
0.49 to 5.39		1.54
0.74 to 3.21		1.52
0.68 to 3.34		1.49
0.58 to 3.88		1.41
0.67 to 3.05		1.40
0.68 to 2.86		1.33
0.63 to 2.84		1.29
0.64 to 2.66		1.25
0.61 to 2.61		1.25
0.44 to 3.82		1.25
0.55 to 2.86		1.24
0.60 to 2.68		1.24
0.61 to 2.57		1.23
0.52 to 3.01		1.23
0.63 to 2.47		1.22
0.44 to 3.38		1.22
0.59 to 2.56		1.19
0.29 to 4.75		1.17
0.58 to 2.44		1.14
0.27 to 4.92		1.14
0.42 to 3.07		1.12
0.54 to 2.36		1.11
0.54 to 2.36		1.09
0.53 to 2.29		1.06
0.42 to 2.59		1.06
0.14 to 6.55		1.05
0.40 to 2.76		1.03
0.37 to 2.95		CANAGLIFLOZIN0.98
0.18 to 5.22		0.98
0.39 to 2.50		0.95
0.17 to 5.08		0.95
0.44 to 2.01		0.89
0.22 to 3.32		0.89
0.40 to 1.97		0.87
0.32 to 2.40		0.85
0.39 to 1.88		0.73
0.02 to 18.06		0.68
0.28 to 1.68		0.63
0.14 to 2.35		0.61
0.01 to 15.97		0.60
0.07 to 3.11		0.59
0.22 to 1.61		0.57
0.01 to 14.69		0.58
0.21 to 1.55		0.51
0.09 to 2.27		0.30
0.01 to 8.38		0.24
0.01 to 3.83
EXENROSI_SC1.15
0.25 to 5.47		4.36
0.11 to 400		3.57
0.40 to 37.14		2.85
0.46 to 19.96		2.60
0.03 to 325		2.52
0.04 to 304		2.28
0.03 to 266		2.13
0.02 to 280		1.97
0.02 to 225		1.79
0.37 to 8.87		1.60
0.34 to 8.30		1.62
0.30 to 8.78		1.60
0.27 to 9.82		1.55
0.33 to 7.56		1.54
0.32 to 7.46		1.51
0.29 to 8.11		1.43
0.31 to 7.03		1.41
0.31 to 6.73		1.33
0.29 to 6.66		1.30
0.29 to 6.26		1.27
0.28 to 6.00		1.26
0.23 to 7.48		1.26
0.27 to 6.35		1.26
0.28 to 5.95		1.25
0.28 to 6.11		1.24
0.25 to 6.51		1.24
0.27 to 5.93		1.22
0.23 to 6.98		1.23
0.27 to 5.91		1.20
0.17 to 8.58		1.18
0.26 to 5.72		1.14
0.16 to 8.85		1.15
0.22 to 6.30		1.13
0.25 to 5.46		1.12
0.24 to 5.43		1.10
0.24 to 5.40		1.07
0.21 to 5.59		1.06
0.10 to 10.01		1.06
0.20 to 5.87		1.04
0.19 to 5.81		1.02
0.19 to 5.68		EXENROSI_SC0.99
0.19 to 5.38		0.96
0.22 to 4.24		0.96
0.21 to 4.67		0.91
0.12 to 6.17		0.90
0.19 to 4.49		0.88
0.16 to 5.02		0.86
0.18 to 4.26		0.71
0.01 to 24.19		0.69
0.14 to 3.66		0.63
0.09 to 4.31		0.61
0.01 to 19.64		0.59
0.05 to 5.10		0.60
0.11 to 3.30		0.57
0.01 to 18.84		0.59
0.11 to 3.12		0.50
0.05 to 4.19		0.30
0.01 to 10.70		0.24
0.01 to 5.32
DAPAGLIFLOZIN1.16
0.62 to 2.14		4.49
0.14 to 336		3.53
0.66 to 24.70		2.88
0.83 to 10.84		2.59
0.03 to 256		2.49
0.05 to 253		2.29
0.03 to 201		2.11
0.02 to 225		1.95
0.02 to 195		1.80
0.82 to 3.99		1.64
0.76 to 3.52		1.62
0.62 to 4.25		1.60
0.50 to 5.21		1.57
0.81 to 3.09		1.55
0.75 to 3.22		1.53
0.63 to 3.82		1.44
0.73 to 2.90		1.43
0.75 to 2.70		1.36
0.69 to 2.71		1.32
0.70 to 2.49		1.28
0.67 to 2.46		1.27
0.48 to 3.88		1.27
0.60 to 2.69		1.27
0.67 to 2.46		1.27
0.68 to 2.42		1.26
0.56 to 2.89		1.26
0.66 to 2.37		1.25
0.48 to 3.16		1.25
0.65 to 2.41		1.21
0.32 to 4.50		1.20
0.66 to 2.20		1.16
0.28 to 4.77		1.16
0.58 to 2.34		1.15
0.59 to 2.18		1.13
0.59 to 2.23		1.12
0.59 to 2.13		1.08
0.46 to 2.50		1.08
0.16 to 6.13		1.08
0.61 to 1.87		1.05
0.40 to 2.88		1.02
0.40 to 2.59		1.01
0.19 to 5.27		DAPAGLIFLOZIN0.98
0.18 to 4.95		0.96
0.49 to 1.88		0.91
0.23 to 3.23		0.91
0.43 to 1.92		0.89
0.34 to 2.33		0.87
0.43 to 1.77		0.75
0.02 to 18.68		0.70
0.29 to 1.67		0.64
0.15 to 2.37		0.62
0.01 to 15.50		0.61
0.07 to 3.02		0.60
0.22 to 1.59		0.58
0.01 to 14.96		0.59
0.23 to 1.56		0.52
0.09 to 2.28		0.29
0.01 to 8.42		0.25
0.01 to 3.79
ROSIGLITAZONE1.18
0.26 to 5.66		4.60
0.11 to 399		3.75
0.42 to 38.99		2.94
0.47 to 20.57		2.72
0.02 to 361		2.62
0.04 to 311		2.29
0.03 to 285		2.26
0.02 to 284		2.06
0.02 to 225		1.86
0.38 to 9.30		1.68
0.34 to 8.30		1.67
0.31 to 9.12		1.65
0.27 to 9.86		1.61
0.33 to 7.71		1.58
0.33 to 7.78		1.57
0.30 to 8.54		1.48
0.31 to 7.19		1.46
0.31 to 6.94		1.40
0.30 to 6.83		1.35
0.29 to 6.44		1.31
0.28 to 6.29		1.32
0.24 to 7.99		1.32
0.28 to 6.55		1.31
0.29 to 6.15		1.30
0.28 to 6.22		1.29
0.25 to 6.89		1.29
0.28 to 6.08		1.28
0.23 to 7.09		1.28
0.28 to 6.11		1.23
0.18 to 8.75		1.22
0.26 to 5.81		1.19
0.16 to 8.46		1.18
0.22 to 6.55		1.17
0.25 to 5.61		1.17
0.25 to 5.52		1.15
0.25 to 5.49		1.11
0.22 to 5.75		1.09
0.10 to 10.71		1.10
0.21 to 6.07		1.09
0.20 to 5.92		1.05
0.20 to 5.89		1.04
0.24 to 4.62		1.02
0.20 to 5.50		ROSIGLITAZONE0.99
0.21 to 4.88		0.92
0.13 to 6.21		0.94
0.19 to 4.63		0.91
0.17 to 5.25		0.90
0.19 to 4.40		0.74
0.02 to 25.98		0.72
0.14 to 3.71		0.65
0.09 to 4.47		0.64
0.01 to 19.36		0.61
0.05 to 5.23		0.62
0.11 to 3.47		0.59
0.01 to 18.95		0.60
0.11 to 3.20		0.53
0.06 to 4.30		0.30
0.01 to 11.61		0.24
0.01 to 5.49
ORFO_PO1.20
0.90 to 1.62		4.56
0.15 to 331		3.66
0.77 to 22.42		2.96
0.98 to 10.07		2.66
0.04 to 267		2.58
0.06 to 258		2.35
0.04 to 210		2.20
0.03 to 216		2.00
0.03 to 197		1.87
1.07 to 3.32		1.69
1.00 to 2.91		1.68
0.77 to 3.77		1.67
0.60 to 4.75		1.63
1.11 to 2.36		1.61
0.99 to 2.62		1.58
0.78 to 3.31		1.50
0.98 to 2.31		1.48
1.08 to 2.08		1.41
0.92 to 2.19		1.37
0.98 to 1.93		1.33
0.97 to 1.82		1.32
0.56 to 3.43		1.32
0.79 to 2.22		1.32
0.90 to 1.95		1.32
0.95 to 1.85		1.31
0.70 to 2.48		1.30
0.95 to 1.80		1.30
0.59 to 2.74		1.29
0.93 to 1.83		1.26
0.37 to 4.24		1.23
0.86 to 1.77		1.20
0.33 to 4.53		1.20
0.56 to 2.60		1.19
0.81 to 1.70		1.17
0.81 to 1.75		1.16
0.81 to 1.65		1.12
0.60 to 2.08		1.11
0.17 to 6.17		1.11
0.52 to 2.35		1.09
0.48 to 2.52		1.06
0.50 to 2.25		1.04
0.21 to 4.80		1.04
0.53 to 2.03		1.01
0.21 to 4.82		ORFO_PO0.94
0.27 to 2.93		0.94
0.56 to 1.57		0.93
0.41 to 2.02		0.91
0.57 to 1.45		0.77
0.02 to 18.80		0.73
0.36 to 1.42		0.68
0.17 to 2.10		0.66
0.02 to 15.44		0.63
0.08 to 2.83		0.62
0.27 to 1.38		0.62
0.01 to 14.12		0.61
0.28 to 1.31		0.54
0.10 to 2.17		0.31
0.01 to 8.48		0.25
0.01 to 3.78
RETA_SC1.27
0.43 to 4.36		4.97
0.14 to 392		3.98
0.62 to 34.48		3.19
0.67 to 16.54		2.92
0.03 to 318		2.78
0.05 to 308		2.54
0.03 to 279		2.38
0.02 to 301		2.14
0.02 to 251		1.97
0.59 to 7.53		1.78
0.55 to 6.62		1.77
0.48 to 7.76		1.76
0.41 to 8.33		1.71
0.57 to 6.14		1.69
0.54 to 6.41		1.68
0.47 to 6.80		1.58
0.52 to 5.60		1.56
0.53 to 5.49		1.48
0.48 to 5.47		1.45
0.49 to 5.03		1.41
0.46 to 4.98		1.41
0.35 to 6.32		1.38
0.44 to 5.18		1.38
0.45 to 5.07		1.39
0.47 to 4.83		1.37
0.41 to 5.47		1.38
0.46 to 4.84		1.37
0.36 to 5.71		1.36
0.45 to 4.82		1.32
0.27 to 7.46		1.31
0.43 to 4.57		1.27
0.23 to 7.63		1.28
0.34 to 5.42		1.26
0.41 to 4.43		1.24
0.41 to 4.33		1.23
0.41 to 4.33		1.18
0.34 to 4.60		1.17
0.13 to 9.42		1.17
0.32 to 4.99		1.16
0.30 to 4.99		1.12
0.30 to 4.61		1.10
0.16 to 8.02		1.10
0.31 to 4.39		1.08
0.16 to 7.47		1.06
0.34 to 3.77		RETA_SC0.99
0.31 to 3.65		0.97
0.26 to 4.11		0.96
0.30 to 3.45		0.84
0.02 to 23.39		0.77
0.22 to 3.04		0.71
0.13 to 3.71		0.70
0.01 to 22.86		0.68
0.07 to 4.53		0.66
0.17 to 2.80		0.66
0.01 to 17.93		0.64
0.17 to 2.78		0.57
0.08 to 3.57		0.33
0.01 to 10.27		0.27
0.01 to 5.38
INS_ASPART1.28
0.84 to 1.98		4.87
0.15 to 347		3.84
0.80 to 25.15		3.18
1.00 to 10.85		2.84
0.04 to 285		2.74
0.06 to 283		2.55
0.04 to 233		2.32
0.03 to 242		2.12
0.03 to 214		1.99
1.05 to 3.77		1.80
0.99 to 3.32		1.80
0.76 to 4.31		1.77
0.61 to 5.33		1.73
1.07 to 2.84		1.71
0.98 to 3.01		1.69
0.79 to 3.75		1.59
0.96 to 2.68		1.58
1.03 to 2.45		1.50
0.90 to 2.59		1.45
0.94 to 2.34		1.41
0.90 to 2.26		1.40
0.57 to 3.84		1.40
0.78 to 2.60		1.40
0.88 to 2.31		1.40
0.91 to 2.21		1.40
0.71 to 2.77		1.39
0.93 to 2.11		1.38
0.60 to 3.14		1.37
0.88 to 2.19		1.34
0.38 to 4.80		1.32
0.83 to 2.14		1.29
0.33 to 5.03		1.28
0.56 to 2.94		1.27
0.79 to 2.05		1.25
0.79 to 2.06		1.24
0.78 to 1.98		1.19
0.60 to 2.37		1.18
0.18 to 6.64		1.19
0.51 to 2.67		1.16
0.49 to 2.76		1.13
0.51 to 2.49		1.11
0.22 to 5.25		1.10
0.52 to 2.32		1.06
0.22 to 5.19		1.06
0.64 to 1.80		1.01
0.27 to 3.18		INS_ASPART0.99
0.42 to 2.32		0.96
0.56 to 1.68		0.82
0.02 to 20.29		0.78
0.37 to 1.59		0.72
0.18 to 2.32		0.69
0.02 to 16.76		0.68
0.08 to 3.07		0.66
0.28 to 1.56		0.65
0.02 to 15.53		0.65
0.28 to 1.50		0.58
0.10 to 2.28		0.33
0.01 to 8.60		0.27
0.01 to 4.27
VISEPE_SC1.29
0.63 to 2.71		4.92
0.16 to 371		4.00
0.72 to 28.11		3.25
0.88 to 12.69		2.91
0.04 to 302		2.81
0.06 to 310		2.55
0.04 to 218		2.39
0.03 to 240		2.22
0.03 to 219		2.01
0.85 to 5.00		1.83
0.79 to 4.35		1.83
0.64 to 5.22		1.81
0.53 to 6.21		1.76
0.83 to 3.86		1.74
0.76 to 3.97		1.72
0.65 to 4.58		1.61
0.74 to 3.66		1.60
0.77 to 3.43		1.52
0.70 to 3.46		1.48
0.71 to 3.17		1.43
0.68 to 3.07		1.44
0.47 to 4.67		1.43
0.60 to 3.40		1.42
0.67 to 3.14		1.42
0.69 to 3.07		1.41
0.57 to 3.65		1.41
0.69 to 3.02		1.39
0.51 to 3.96		1.39
0.67 to 3.06		1.35
0.33 to 5.47		1.33
0.63 to 2.94		1.31
0.31 to 5.75		1.29
0.46 to 3.66		1.29
0.61 to 2.82		1.27
0.59 to 2.82		1.25
0.59 to 2.71		1.21
0.48 to 3.03		1.21
0.16 to 7.16		1.22
0.43 to 3.28		1.18
0.42 to 3.45		1.15
0.42 to 3.12		1.14
0.20 to 6.09		1.12
0.43 to 2.97		1.10
0.19 to 5.97		1.08
0.50 to 2.41		1.03
0.24 to 3.81		1.01
0.43 to 2.40		VISEPE_SC0.98
0.43 to 2.22		0.84
0.02 to 20.59		0.78
0.31 to 2.10		0.72
0.16 to 2.75		0.70
0.02 to 18.63		0.68
0.08 to 3.62		0.67
0.24 to 1.94		0.67
0.01 to 16.07		0.66
0.23 to 1.83		0.59
0.10 to 2.66		0.33
0.01 to 9.40		0.28
0.01 to 4.35
INS_LISPRO1.33
0.93 to 1.91		5.05
0.17 to 348		4.05
0.82 to 24.92		3.27
1.08 to 11.21		2.95
0.04 to 284		2.85
0.06 to 280		2.57
0.04 to 233		2.43
0.03 to 242		2.24
0.03 to 216		2.06
1.19 to 3.70		1.87
1.05 to 3.37		1.86
0.82 to 4.25		1.86
0.65 to 5.27		1.80
1.28 to 2.57		1.78
1.10 to 2.91		1.75
0.84 to 3.69		1.66
1.06 to 2.59		1.64
1.13 to 2.39		1.55
1.00 to 2.48		1.51
1.04 to 2.21		1.47
0.98 to 2.20		1.46
0.61 to 3.90		1.47
0.87 to 2.48		1.46
1.00 to 2.16		1.46
1.02 to 2.09		1.45
0.76 to 2.82		1.45
0.99 to 2.12		1.43
0.63 to 3.15		1.43
0.97 to 2.11		1.39
0.40 to 4.83		1.37
0.91 to 2.06		1.33
0.36 to 5.05		1.33
0.60 to 2.99		1.32
0.90 to 1.92		1.30
0.88 to 1.99		1.28
0.86 to 1.91		1.24
0.65 to 2.36		1.24
0.19 to 6.74		1.23
0.56 to 2.68		1.20
0.53 to 2.82		1.18
0.53 to 2.54		1.16
0.23 to 5.50		1.14
0.57 to 2.31		1.11
0.23 to 5.35		1.10
0.69 to 1.75		1.04
0.29 to 3.32		1.04
0.60 to 1.77		1.02
0.45 to 2.31		INS_LISPRO0.86
0.02 to 21.54		0.80
0.40 to 1.63		0.75
0.18 to 2.35		0.71
0.02 to 17.61		0.71
0.09 to 3.24		0.69
0.29 to 1.56		0.68
0.02 to 15.85		0.68
0.31 to 1.50		0.60
0.11 to 2.40		0.34
0.01 to 9.25		0.28
0.01 to 4.13
ECNO_SC1.56
0.07 to 62.96		6.73
0.06 to 1483		4.86
0.15 to 279		3.89
0.14 to 185		3.52
0.02 to 1230		3.69
0.02 to 1087		3.30
0.02 to 943		3.03
0.01 to 1037		2.83
0.01 to 821		2.44
0.10 to 98.94		2.20
0.09 to 92.92		2.21
0.08 to 91.53		2.17
0.08 to 99.35		2.12
0.09 to 85.72		2.09
0.08 to 83.99		2.09
0.08 to 90.28		1.94
0.08 to 80.11		1.92
0.08 to 79.05		1.84
0.08 to 74.41		1.79
0.08 to 71.52		1.73
0.07 to 70.71		1.74
0.06 to 76.66		1.73
0.07 to 70.76		1.74
0.07 to 71.82		1.71
0.07 to 68.86		1.71
0.07 to 68.02		1.71
0.07 to 69.20		1.67
0.07 to 72.80		1.68
0.07 to 68.15		1.63
0.06 to 74.96		1.61
0.06 to 63.51		1.57
0.05 to 70.77		1.53
0.06 to 63.83		1.55
0.07 to 62.41		1.52
0.06 to 63.21		1.52
0.06 to 61.74		1.42
0.06 to 59.59		1.48
0.04 to 79.60		1.44
0.06 to 65.04		1.43
0.06 to 60.78		1.37
0.06 to 57.54		1.41
0.04 to 71.98		1.34
0.05 to 58.06		1.34
0.04 to 62.76		1.29
0.05 to 54.13		1.19
0.04 to 57.68		1.22
0.05 to 50.62		1.19
0.05 to 52.00		1.17
0.05 to 47.86		ECNO_SC0.94
0.04 to 38.96		0.86
0.03 to 39.87		0.84
0.01 to 110		0.80
0.02 to 41.15		0.81
0.03 to 33.82		0.76
0.01 to 88.65		0.80
0.03 to 33.57		0.69
0.02 to 37.03		0.41
0.00 to 49.64		0.32
0.00 to 31.39
ICOSEMA_SC1.65
0.90 to 3.09		6.34
0.21 to 471		5.07
0.96 to 34.38		4.08
1.20 to 15.46		3.67
0.05 to 348		3.52
0.07 to 364		3.27
0.04 to 306		3.00
0.04 to 322		2.76
0.03 to 282		2.57
1.18 to 5.59		2.33
1.09 to 4.97		2.33
0.90 to 6.15		2.29
0.73 to 7.33		2.24
1.17 to 4.36		2.22
1.09 to 4.54		2.19
0.89 to 5.37		2.05
1.05 to 4.09		2.03
1.10 to 3.88		1.93
0.99 to 3.88		1.88
1.01 to 3.59		1.82
0.97 to 3.49		1.82
0.68 to 5.42		1.81
0.88 to 3.88		1.81
0.95 to 3.54		1.80
0.99 to 3.46		1.80
0.82 to 4.04		1.79
0.99 to 3.32		1.78
0.68 to 4.51		1.77
0.95 to 3.42		1.74
0.44 to 6.61		1.70
0.90 to 3.30		1.66
0.40 to 6.84		1.65
0.65 to 4.29		1.64
0.85 to 3.18		1.61
0.85 to 3.18		1.59
0.84 to 3.08		1.53
0.68 to 3.49		1.51
0.22 to 9.37		1.53
0.61 to 3.94		1.50
0.58 to 3.98		1.46
0.60 to 3.63		1.45
0.27 to 7.38		1.42
0.60 to 3.50		1.38
0.27 to 7.10		1.37
0.71 to 2.76		1.30
0.33 to 4.62		1.29
0.63 to 2.72		1.28
0.48 to 3.24		1.24
0.61 to 2.53		1.06
0.03 to 26.40		ICOSEMA_SC0.92
0.21 to 3.20		0.88
0.02 to 22.95		0.87
0.11 to 4.40		0.86
0.55 to 1.36		0.85
0.02 to 21.09		0.84
0.33 to 2.16		0.75
0.13 to 3.16		0.42
0.01 to 11.73		0.35
0.01 to 5.47
LOTI_PO1.78
0.60 to 6.94		7.11
0.21 to 541		5.59
0.77 to 49.07		4.48
0.99 to 25.26		4.12
0.05 to 440		3.97
0.07 to 438		3.60
0.05 to 362		3.40
0.03 to 420		3.15
0.04 to 349		2.78
0.84 to 11.59		2.52
0.77 to 10.26		2.50
0.65 to 11.37		2.50
0.57 to 13.10		2.40
0.79 to 9.51		2.38
0.76 to 9.62		2.38
0.65 to 10.92		2.20
0.72 to 8.85		2.19
0.73 to 8.63		2.10
0.67 to 8.25		2.03
0.67 to 7.84		1.96
0.65 to 7.72		1.99
0.48 to 10.05		1.95
0.60 to 8.07		1.95
0.64 to 7.64		1.94
0.65 to 7.68		1.94
0.57 to 8.37		1.93
0.64 to 7.53		1.92
0.52 to 8.62		1.90
0.64 to 7.58		1.89
0.37 to 11.20		1.83
0.60 to 7.20		1.82
0.32 to 11.69		1.80
0.47 to 8.21		1.75
0.58 to 6.97		1.74
0.57 to 6.96		1.72
0.56 to 6.78		1.66
0.48 to 7.19		1.66
0.19 to 14.49		1.66
0.43 to 7.68		1.65
0.43 to 7.52		1.58
0.43 to 7.32		1.58
0.23 to 11.64		1.55
0.42 to 6.88		1.55
0.22 to 11.50		1.48
0.48 to 5.93		1.40
0.27 to 7.93		1.39
0.43 to 5.62		1.38
0.36 to 6.32		1.33
0.43 to 5.47		1.16
0.03 to 34.05		1.08
0.31 to 4.66		LOTI_PO0.98
0.02 to 28.78		0.94
0.10 to 7.18		0.92
0.25 to 4.32		0.93
0.02 to 27.63		0.92
0.24 to 4.15		0.81
0.11 to 5.33		0.46
0.01 to 14.66		0.38
0.01 to 8.02
BOFANG_SC1.85
0.08 to 75.80		7.90
0.07 to 1801		5.90
0.16 to 342		4.72
0.17 to 228		4.42
0.02 to 1481		4.39
0.03 to 1223		3.95
0.02 to 1270		3.70
0.02 to 1187		3.41
0.02 to 920		2.85
0.12 to 128		2.62
0.10 to 113		2.65
0.10 to 116		2.65
0.09 to 116		2.50
0.11 to 104		2.51
0.10 to 100		2.48
0.10 to 108		2.31
0.09 to 97.41		2.28
0.09 to 94.60		2.19
0.09 to 87.45		2.10
0.09 to 85.72		2.04
0.09 to 83.78		2.07
0.08 to 92.02		2.05
0.09 to 87.71		2.05
0.08 to 85.63		2.04
0.08 to 82.93		2.02
0.08 to 86.99		2.01
0.08 to 82.01		2.00
0.08 to 90.10		1.98
0.08 to 82.24		1.91
0.07 to 96.10		1.93
0.08 to 80.25		1.84
0.06 to 85.44		1.86
0.07 to 83.16		1.84
0.08 to 74.36		1.82
0.08 to 75.76		1.81
0.07 to 75.44		1.73
0.07 to 73.81		1.73
0.04 to 101		1.72
0.07 to 73.99		1.70
0.06 to 71.79		1.63
0.06 to 71.14		1.64
0.05 to 88.05		1.61
0.06 to 68.11		1.57
0.05 to 81.38		1.53
0.06 to 60.92		1.43
0.04 to 66.87		1.46
0.06 to 60.11		1.42
0.05 to 64.75		1.41
0.06 to 59.24		1.19
0.01 to 167		1.13
0.04 to 47.14		1.03
0.03 to 51.31		BOFANG_SC0.94
0.02 to 54.49		0.96
0.04 to 43.80		0.93
0.01 to 143		0.94
0.04 to 44.40		0.82
0.02 to 43.77		0.49
0.00 to 63.50		0.38
0.00 to 39.72
DANU_PO1.88
0.43 to 14.22		7.87
0.18 to 820		5.97
0.71 to 86.15		4.68
0.74 to 47.89		4.46
0.04 to 659		4.32
0.07 to 567		4.03
0.04 to 514		3.60
0.04 to 509		3.40
0.03 to 442		2.95
0.62 to 23.29		2.66
0.56 to 21.48		2.68
0.49 to 23.02		2.62
0.43 to 24.38		2.56
0.58 to 19.75		2.52
0.54 to 20.25		2.51
0.49 to 20.61		2.37
0.52 to 18.44		2.32
0.53 to 17.98		2.22
0.48 to 17.89		2.15
0.49 to 16.23		2.08
0.48 to 15.87		2.13
0.37 to 18.92		2.07
0.44 to 16.37		2.08
0.46 to 15.74		2.06
0.47 to 15.77		2.08
0.42 to 16.93		2.05
0.47 to 15.86		2.06
0.39 to 17.21		2.04
0.46 to 15.79		2.03
0.29 to 20.03		1.96
0.44 to 14.66		1.96
0.26 to 19.81		1.89
0.36 to 16.03		1.87
0.42 to 14.38		1.86
0.41 to 14.08		1.83
0.42 to 14.13		1.77
0.36 to 14.13		1.76
0.16 to 23.52		1.78
0.34 to 15.02		1.73
0.33 to 14.85		1.67
0.32 to 14.90		1.68
0.20 to 20.36		1.63
0.33 to 13.59		1.64
0.19 to 18.80		1.58
0.35 to 12.26		1.48
0.22 to 14.45		1.48
0.33 to 11.81		1.46
0.28 to 12.12		1.41
0.31 to 10.86		1.25
0.02 to 48.17		1.16
0.23 to 9.44		1.06
0.14 to 10.31		1.06
0.02 to 41.55		DANU_PO0.99
0.19 to 8.41		0.99
0.02 to 40.18		0.94
0.19 to 8.25		0.86
0.09 to 9.11		0.49
0.01 to 22.21		0.42
0.01 to 10.72
INS_ICODEC1.93
0.92 to 4.20		7.34
0.24 to 542		5.88
1.05 to 42.75		4.79
1.31 to 19.66		4.24
0.05 to 424		4.09
0.08 to 439		3.84
0.05 to 351		3.52
0.04 to 389		3.25
0.04 to 342		3.00
1.26 to 7.30		2.71
1.13 to 6.67		2.72
0.95 to 7.85		2.68
0.79 to 9.18		2.61
1.21 to 5.90		2.60
1.12 to 5.97		2.55
0.95 to 6.96		2.40
1.09 to 5.42		2.38
1.12 to 5.30		2.26
1.02 to 5.22		2.20
1.04 to 4.84		2.14
1.00 to 4.68		2.13
0.72 to 6.99		2.11
0.91 to 5.08		2.11
0.98 to 4.80		2.12
1.00 to 4.68		2.11
0.87 to 5.30		2.10
1.01 to 4.56		2.07
0.75 to 5.84		2.07
0.97 to 4.65		2.02
0.50 to 8.37		1.99
0.92 to 4.53		1.94
0.46 to 8.56		1.92
0.70 to 5.36		1.90
0.88 to 4.23		1.89
0.88 to 4.28		1.87
0.87 to 4.11		1.79
0.72 to 4.54		1.77
0.24 to 11.76		1.80
0.64 to 5.12		1.75
0.63 to 5.13		1.70
0.62 to 4.65		1.68
0.30 to 9.40		1.67
0.63 to 4.51		1.62
0.29 to 8.83		1.60
0.73 to 3.64		1.51
0.36 to 5.84		1.51
0.64 to 3.58		1.48
0.52 to 4.22		1.44
0.64 to 3.41		1.24
0.03 to 32.78		1.17
0.74 to 1.81		1.08
0.23 to 4.04		1.04
0.02 to 28.01		1.01
0.12 to 5.40		INS_ICODEC0.98
0.02 to 24.06		0.98
0.35 to 2.78		0.86
0.14 to 4.00		0.49
0.01 to 14.47		0.41
0.01 to 6.57
EXENIMP_IMPLANT1.96
0.09 to 79.31		8.27
0.07 to 2026		6.40
0.18 to 372		4.98
0.18 to 229		4.69
0.02 to 1369		4.81
0.03 to 1398		4.16
0.02 to 1411		3.90
0.02 to 1304		3.53
0.02 to 1119		3.02
0.13 to 129		2.74
0.11 to 122		2.74
0.11 to 121		2.77
0.10 to 135		2.68
0.12 to 111		2.62
0.12 to 113		2.61
0.11 to 117		2.45
0.11 to 98.29		2.41
0.10 to 100		2.31
0.10 to 97.27		2.24
0.10 to 91.23		2.16
0.10 to 89.78		2.21
0.09 to 100		2.15
0.09 to 92.29		2.13
0.10 to 87.84		2.15
0.09 to 88.89		2.14
0.09 to 93.78		2.15
0.09 to 87.73		2.16
0.09 to 90.08		2.12
0.09 to 85.18		2.05
0.07 to 106		2.03
0.09 to 85.28		2.01
0.07 to 103		1.93
0.08 to 93.15		1.93
0.08 to 80.06		1.91
0.08 to 79.01		1.90
0.08 to 78.92		1.80
0.07 to 78.29		1.83
0.05 to 119		1.84
0.07 to 82.15		1.75
0.07 to 79.21		1.74
0.07 to 74.71		1.77
0.05 to 96.94		1.73
0.07 to 77.63		1.69
0.05 to 86.89		1.62
0.07 to 71.31		1.52
0.06 to 74.77		1.53
0.06 to 64.20		1.50
0.06 to 69.51		1.47
0.06 to 63.55		1.31
0.01 to 160		1.18
0.05 to 50.60		1.08
0.04 to 51.92		1.08
0.01 to 158		1.01
0.02 to 63.54		1.02
0.04 to 46.12		EXENIMP_IMPLANT0.99
0.04 to 43.56		0.87
0.02 to 45.70		0.51
0.00 to 79.81		0.42
0.00 to 43.30
PIOGLITAZONE1.98
0.96 to 4.09		7.46
0.24 to 579		5.96
1.05 to 42.43		4.94
1.32 to 18.84		4.37
0.05 to 443		4.26
0.08 to 440		3.83
0.06 to 362		3.63
0.04 to 379		3.34
0.04 to 334		3.05
1.37 to 6.99		2.78
1.18 to 6.49		2.75
1.00 to 7.82		2.77
0.77 to 9.29		2.68
1.25 to 5.70		2.65
1.16 to 5.93		2.59
0.98 to 7.00		2.46
1.13 to 5.32		2.44
1.16 to 5.08		2.33
1.06 to 5.05		2.26
1.07 to 4.69		2.19
1.02 to 4.61		2.17
0.74 to 6.71		2.16
0.96 to 5.00		2.16
1.04 to 4.54		2.17
1.03 to 4.57		2.15
0.87 to 5.38		2.15
1.03 to 4.47		2.12
0.77 to 5.83		2.12
1.03 to 4.40		2.06
0.53 to 8.26		2.04
0.98 to 4.20		1.97
0.43 to 8.60		1.98
0.72 to 5.28		1.96
0.92 to 4.21		1.93
0.91 to 4.12		1.90
0.90 to 4.04		1.83
0.74 to 4.53		1.80
0.26 to 11.64		1.84
0.67 to 4.88		1.80
0.63 to 5.02		1.73
0.64 to 4.77		1.71
0.32 to 9.10		1.71
0.64 to 4.27		1.66
0.31 to 8.76		1.65
0.77 to 3.57		1.55
0.36 to 5.91		1.55
0.67 to 3.55		1.53
0.55 to 4.37		1.48
0.67 to 3.27		1.25
0.03 to 32.32		1.19
0.46 to 3.06		1.09
0.24 to 4.21		1.06
0.02 to 27.74		1.06
0.12 to 5.38		1.02
0.36 to 2.85		1.01
0.02 to 24.18		PIOGLITAZONE0.88
0.15 to 4.11		0.50
0.01 to 14.35		0.42
0.01 to 6.66
HRS7535_PO2.21
0.58 to 11.77		9.12
0.22 to 850		7.04
0.88 to 76.45		5.54
1.00 to 42.46		5.21
0.05 to 593		5.01
0.08 to 622		4.59
0.05 to 502		4.26
0.04 to 515		3.89
0.04 to 474		3.45
0.83 to 19.74		3.12
0.75 to 17.53		3.15
0.66 to 18.00		3.13
0.58 to 21.42		2.98
0.76 to 15.95		2.95
0.73 to 16.26		2.94
0.67 to 17.72		2.76
0.71 to 14.89		2.74
0.72 to 14.53		2.60
0.67 to 13.95		2.52
0.66 to 13.42		2.45
0.64 to 12.92		2.49
0.50 to 16.07		2.44
0.60 to 13.70		2.42
0.63 to 13.08		2.42
0.63 to 12.79		2.41
0.58 to 13.68		2.41
0.64 to 12.76		2.41
0.53 to 14.58		2.37
0.63 to 12.46		2.32
0.38 to 18.67		2.27
0.59 to 12.26		2.29
0.34 to 17.55		2.24
0.49 to 13.58		2.18
0.56 to 11.72		2.17
0.56 to 11.53		2.15
0.55 to 11.42		2.05
0.49 to 11.94		2.08
0.21 to 21.88		2.08
0.45 to 12.60		2.06
0.44 to 12.61		1.97
0.44 to 11.50		1.98
0.24 to 18.71		1.91
0.44 to 11.18		1.89
0.23 to 17.65		1.84
0.46 to 9.88		1.77
0.28 to 12.42		1.74
0.44 to 9.61		1.71
0.38 to 10.51		1.66
0.42 to 9.06		1.46
0.03 to 52.32		1.34
0.32 to 7.88		1.24
0.19 to 9.31		1.21
0.02 to 45.57		1.16
0.11 to 11.35		1.17
0.25 to 7.04		1.15
0.02 to 40.55		1.14
0.24 to 6.79		HRS7535_PO0.59
0.01 to 20.72		0.48
0.01 to 11.43
DULAMACU_SC3.91
0.14 to 153		16.31
0.14 to 3729		12.56
0.32 to 693		9.82
0.32 to 418		9.02
0.04 to 2690		8.54
0.11 to 2145		8.09
0.04 to 2394		7.56
0.03 to 2508		6.74
0.03 to 2081		5.99
0.22 to 247		5.51
0.20 to 215		5.52
0.19 to 217		5.41
0.18 to 242		5.29
0.19 to 205		5.25
0.20 to 205		5.12
0.19 to 208		4.87
0.18 to 194		4.80
0.18 to 189		4.51
0.17 to 182		4.45
0.16 to 172		4.27
0.16 to 171		4.25
0.14 to 196		4.26
0.16 to 179		4.26
0.16 to 168		4.28
0.16 to 162		4.26
0.15 to 169		4.22
0.16 to 166		4.19
0.15 to 167		4.17
0.16 to 165		4.19
0.13 to 178		3.99
0.15 to 159		3.98
0.11 to 189		3.92
0.13 to 166		3.83
0.14 to 153		3.83
0.14 to 150		3.78
0.14 to 146		3.58
0.13 to 149		3.62
0.08 to 213		3.65
0.13 to 150		3.55
0.12 to 143		3.37
0.12 to 139		3.35
0.09 to 178		3.40
0.12 to 142		3.34
0.09 to 166		3.26
0.12 to 127		3.05
0.10 to 134		3.05
0.12 to 120		3.01
0.11 to 130		2.96
0.11 to 114		2.45
0.02 to 311		2.36
0.09 to 96.23		2.16
0.07 to 91.16		2.06
0.02 to 274		2.04
0.05 to 110		2.06
0.07 to 83.33		1.94
0.01 to 240		2.00
0.07 to 84.45		1.71
0.05 to 82.64		DULAMACU_SC0.82
0.01 to 73.65
BGM050_SC4.67
0.32 to 136		20.06
0.22 to 3652		14.73
0.62 to 634		12.01
0.67 to 386		11.48
0.06 to 2627		11.15
0.09 to 2902		10.32
0.06 to 2077		9.29
0.05 to 2612		8.38
0.04 to 2407		7.26
0.49 to 211		6.66
0.45 to 194		6.66
0.41 to 223		6.72
0.37 to 218		6.27
0.44 to 191		6.28
0.43 to 184		6.23
0.39 to 192		5.84
0.40 to 166		5.76
0.40 to 166		5.46
0.37 to 160		5.37
0.37 to 155		5.18
0.36 to 152		5.21
0.32 to 169		5.17
0.35 to 148		5.17
0.35 to 146		5.12
0.36 to 153		5.12
0.35 to 155		5.08
0.36 to 149		5.09
0.32 to 152		5.05
0.35 to 154		4.92
0.27 to 169		4.77
0.35 to 141		4.90
0.24 to 177		4.82
0.29 to 145		4.61
0.33 to 130		4.58
0.31 to 134		4.50
0.32 to 130		4.39
0.28 to 137		4.39
0.18 to 179		4.32
0.27 to 138		4.23
0.27 to 141		4.13
0.26 to 123		4.17
0.19 to 158		4.05
0.26 to 125		4.09
0.18 to 149		3.93
0.26 to 116		3.76
0.19 to 127		3.64
0.23 to 117		3.62
0.23 to 115		3.53
0.24 to 101		3.13
0.03 to 266		2.83
0.18 to 87.29		2.61
0.12 to 93.85		2.64
0.03 to 234		2.38
0.09 to 98.47		2.46
0.15 to 79.00		2.36
0.02 to 220		2.37
0.15 to 74.24		2.09
0.09 to 78.95		1.23
0.01 to 119		BGM050_SC

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau)
0.144 (95% CrI 0.068 to 0.228), log scale
Residual deviance
422.6 for 453 data points
DIC
676.3 (pD 253.7)
Largest R-hat
1.002
Smallest ESS
bulk 1,135, tail 2,130
Divergent transitions
0
Convergence
All criteria met
Priors
PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 7.5 or less
  • NoteOutcome assessment, time point: selected time points span 0.43 to 391.35 weeks
  • NoteOutcome assessment, analysis set: mixed: completers 2, full_analysis 7, modified_itt 13, other 4, randomized 14, safety 171
  • NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, ADA severe hypoglycemia 1, adverse event term hypoglycemia, threshold not stated 1, all cause deaths 1, confirmed: severe or plasma glucose below 3.1 mmol/L 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, EAC confirmed MACE; components not defined 1, glucose below 3.0 mmol/L; no severe events in any arm 1, Grade 3, needing third party assistance 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, Hypoglycemia adverse event term 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia glucose 3.9 mmol/L or lower; both events mild 1, hypoglycemia reported as serious adverse event; level not stated 1, hypoglycemia requiring medical assistance 1, investigator reported symptomatic hypoglycemia 1, level 3 severe hypoglycemia 2, major hypoglycemia, subject unable to self treat 1, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, not stated 152, participants with serious adverse events 2, patient reported hypoglycemia events 1, Patients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuation 1, plasma glucose 54 mg/dL or lower 1, serious acute kidney injury 1, serious adverse events 1, serious AEs including 4 week follow up 1, serious hypoglycaemia adverse event 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia 1, severe hypoglycemia by ADA classification 1, severe hypoglycemia needing assistance of another person 1, severe hypoglycemia needing emergency care 1, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing third party assistance 1, Severe hypoglycemia requiring assistance of another person 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe hypoglycemia, serious adverse event 1, severe hypoglycemia, undefined 1, severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms 1, severe symptomatic hypoglycemia needing assistance 1, severe, requiring assistance of another person 2, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement 1, symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, symptomatic mild hypoglycemia, no glucose threshold printed 1, TEAE leading to death 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1, Zero implied by no hypoglycemia episodes of any kind 1
  • NoteOutcome assessment, adjudicated: mixed: not stated 207, yes 4
  • NoteOutcome assessment, proportion method: mixed: not stated 208, observed 3
  • NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 204, treatment_policy 1, while_on_treatment 6
  • NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 207, treatment_policy 4
  • NoteRisk of bias, blinding: mixed: double_blind 120, not_reported 2, open_label 83, single_blind 6
  • NoteRisk of bias, funding: mixed: industry 193, mixed 9, non_industry 8, not_reported 1
  • NoteData handling, input conversions: arms_combined 86, count_from_percent 7, printed_denominator 26
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT0313168730safetysevere hypoglycemia needing assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988156safetyhypoglycemia adverse event, definition not statednot statednot statednot statednot statednot stateddouble_blindindustry2008age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT0540796112safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out)
NCT0077568426.07randomizednot statednot statednot statednot statednot statednot statedopen_labelnon_industry2008age 18 to 70; fasting glucose 110 to 159 mg/dL off glucose lowering drugs; early T2D or impaired fasting glucose
NCT0232596016safetynot statednot statednot statednot statednot statednot statedopen_labelmixed2015age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
NCT0051811524safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2007age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin
NCT0129641226safetyinvestigator reported symptomatic hypoglycemianot statednot statednot statednot statednot statedopen_labelindustry2011age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
DUAL™ I China27safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2017Chinese adults 18 y or older; HbA1c 7.0 to 10.0; BMI 40 or less; metformin with or without one OAD
NCT0008240752modified_ittnot statednot statednot statednot statednot statednot statedopen_labelindustry2003Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40
NCT00838916164safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2009age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-656safetynot statednot statedyesnot statedwhile_on_treatmentnot statedopen_labelindustry2020adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
PIONEER 457safetynot statednot statednot statednot statedwhile_on_treatmenttreatment_policydouble_blindindustry2016Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
NCT0496550624safetyglucose below 3.0 mmol/L; no severe events in any armnot statednot statednot statednot statednot stateddouble_blindindustry2021age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
MAGNA VICTORIA26safetynot statednot statednot statednot statednot statednot stateddouble_blindmixed2015South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
REWIND365.26safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2011age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 257safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2022adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin58safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
STEP HFpEF DM57safetynot statednot statedyesnot statednot statednot stateddouble_blindindustry2021age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
DUAL™IV26safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2012adults 18 or older; HbA1c 7.0 to 9.0 percent; BMI 40 or less; SU with or without metformin; insulin and GLP-1 RA naive
Lixilan-O-AP24.43safetydocumented plasma glucose below 3.0 mmol/L regardless of symptomsnot statednot statednot statednot statednot statedopen_labelindustry2019adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT0147647524safetyDocumented symptomatic, plasma glucose 3.9 mmol/L or lowernot statednot statednot statednot statednot statedopen_labelindustry2011Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-132safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2024age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB11924safetySevere hypoglycemia needing medical treatmentnot statednot statednot statednot statednot stateddouble_blindindustry2020age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT0100110416safetyserious AEs including 4 week follow upnot statednot statednot statednot statednot stateddouble_blindindustry2009Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 1057safetynot statednot statedyesnot statedwhile_on_treatmenttreatment_policysingle_blindindustry2017Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT0284623352.14randomizednot statednot statednot statednot statednot statednot statedopen_labelnon_industry2016age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin
AWARD-752safetyHypoglycaemia reported as treatment emergent adverse eventnot statednot statednot statedtreatment_policytreatment_policysingle_blindindustry2012adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT0158423226safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2012Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT0323505058safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin
NCT0423595928safetyhypoglycemia glucose 3.9 mmol/L or lower; both events mildnot statednot statednot statednot statednot stateddouble_blindindustry2020Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more
AWARD-1024safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2015T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin
SUSTAIN™ 361safetynot statednot statednot statednot statedwhile_on_treatmentnot statedopen_labelindustry2013age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
NCT0039371852safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2006age 20 or older; HbA1c 7.4 to 10.4 percent NGSP; with or without prior oral agents
EGO16safetyserious adverse eventsnot statednot statednot statednot statednot stateddouble_blindindustry2008overweight or obese adults with type 2 diabetes
NCT0076581730full_analysisminor: symptoms with glucose below 3 mmol/L, self treated or resolvednot statednot statednot statednot statednot stateddouble_blindindustry2008adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT0102988626modified_ittnot statednot statednot statednot statedwhile_on_treatmentnot statedopen_labelindustry2010adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
LIXILAN JP-L26.43randomizednot statednot statednot statednot statedwhile_on_treatmenttreatment_policyopen_labelindustry2016Japanese adults; T2D over 1 year; HbA1c 7.5 to 9.5 on basal insulin plus 1 or 2 oral drugs
SUSTAIN 1152safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2018adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
NCT0276539916safetynot statednot statednot statednot statednot statednot statedsingle_blindmixed2015age 30 to 75; BMI 27 to 40; HbA1c 6 to 9 percent; lifestyle or metformin
SUSTAIN 745safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2016age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background
NCT0079147912safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008adults with type 2 diabetes on no background glucose lowering drug
NCT0301068352.14randomizednot statednot statednot statednot statednot statednot statedsingle_blindnot_reported2015newly diagnosed treatment naive type 2 diabetes; no cardiovascular, liver or kidney disease
REMODEL57randomizedsevere hypoglycemianot statednot statednot statednot statednot stateddouble_blindindustry2021T2D with HbA1c 9.0 percent or less; eGFR 30 to 75; UACR 20 to under 5000 mg/g
NCT0063727326safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin
SURPASS-144safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2019adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days
NCT00717457104safetyadverse event term hypoglycemia, threshold not statednot statednot statednot statednot statednot statedopen_labelindustry2008age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD
NCT0097693724safetysevere symptomatic hypoglycemia needing assistancenot statednot statednot statednot statednot stateddouble_blindindustry2009age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
NCT0051607412modified_ittnot statednot statednot statednot statednot statednot stateddouble_blindindustry2007age 18 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; metformin and/or thiazolidinedione
ACHIEVE-357safetyhypoglycemia reported as serious adverse event; level not statednot statednot statednot statednot statednot statedopen_labelindustry2023adults T2D on metformin; HbA1c 7.0 to 10.5 percent
AWARD-928safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014adults with T2D on basal insulin glargine with or without metformin
NCT0557997728safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
COMBINE 157safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2022adults 18+; HbA1c 7.0-10.0%; BMI 40 or less; basal insulin 20-80 U/day; eGFR 30 or more
TRANSITION-T2D26randomizednot statednot statednot statednot statednot statednot statedopen_labelindustry2021age 18 to 75; HbA1c 7.5 or lower on basal bolus insulin up to 120 U per day
SUSTAIN 936safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
GETGOAL-L-ASIA24safetysymptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recoverynot statednot statednot statednot statednot stateddouble_blindindustry2009age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT0486778540safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2021age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 25 to 50; diet and exercise or stable metformin
GETGOAL-S120safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
LIRA-PRIME105safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2016adults; HbA1c 7.5 to 9.0 percent; stable metformin monotherapy
PIONEER 1231safetyADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all armsnot statednot statednot statednot statednot stateddouble_blindindustry2019adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent
NCT0061279420modified_ittnot statednot statednot statednot statednot statednot stateddouble_blindindustry2007Japanese T2D age 20 to 75; weight 50 kg or more; HbA1c 6.5 to 10 percent; diet or oral drugs
NCT03596450104safetyserious acute kidney injurynot statednot statednot statednot statednot statedopen_labelindustry2018adults with type 2 diabetes on metformin, later up to 2 oral drugs, needing intensification
NCT0658976552safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2024age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
SUSTAIN 1035safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2017adults with T2D, HbA1c 7.0 to 11.0 percent on 1 to 3 oral drugs
NCT011754734.43safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2010age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more
NCT0395175332safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2019age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT0096066130othernot statednot statednot statednot statednot statednot statedopen_labelindustry2009age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT0093553226safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2009type 2 diabetes on biguanide with or without thiazolidinedione
NCT0200868226safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2013Chinese adults 18 to 80; HbA1c 7.0 to 10.0 on metformin; BMI 45 or lower
NCT035559949safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2018adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone
NCT0382989116full_analysispatient reported hypoglycemia eventsnot statednot statednot statednot statednot statedopen_labelnon_industry2018age 18 to 70; diabetes 6 months or more on stable oral agents; HbA1c 7.5 to 11.0 percent; BMI 21 to 35
NCT0222938338safetyminor: symptomatic, glucose below 3.0 mmol/L, not majornot statednot statednot statednot statednot stateddouble_blindindustry2014adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT0208111822safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
NCT0057782424full_analysisSevere hypoglycemia requiring assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2008age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
ATTAIN-274safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023adults with type 2 diabetes; BMI 27 or higher; HbA1c 7.0 to 10.0 percent
NCT0297332126.4safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2016adults with type 2 diabetes and overweight or obesity
NCT0114942126safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2010adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT0043495426full_analysisnot statednot statednot statednot statednot statednot statedopen_labelindustry2007adults with T2D on metformin, HbA1c 6.5 to 10.0 percent
NCT02229396104safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 or older; HbA1c 8.0 to 12.0 percent on metformin 1500 mg/d or more
GetGoal-Duo124.43safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2009T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT0155827152safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2012Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017164safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2009age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT0039574652safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2006age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea
NCT0114762748randomizednot statednot statednot statednot statednot statednot statedopen_labelmixed2010newly diagnosed drug naive T2D; age 30 to 70; HbA1c 7 to 10 percent; BMI 20 to 35
GRADE365.26safetysevere hypoglycemia, serious adverse eventnot statednot statednot statednot statednot statedsingle_blindmixed2013age at diagnosis 30 or older; T2D under 10 years; HbA1c 6.8 to 8.5 percent; metformin 1000 mg/day or more
NCT0575989718safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™135safetysevere hypoglycemia by ADA classificationnot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
GetGoal-O24.43safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2013age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher
NCT01144338391.35safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2010age 18 or older; HbA1c 6.5 to 10.0 percent; eGFR 30 or more
NCT0409375244safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2019adults with T2D on metformin with or without sulfonylurea
NCT0161743427safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2012age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin
NCT0013533020randomizednot statednot statednot statednot statednot statednot statedopen_labelindustry2005age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only
LIRA-Ramadan™30safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT022009914.43safetysevere hypoglycemia needing third party assistancenot statednot statednot statednot statednot statedopen_labelindustry2014age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
NCT0009750064safetyHypoglycemia adverse event termnot statednot statednot statednot statednot statedopen_labelindustry2004age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin
ACHIEVE-542safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023adults with T2D on insulin glargine with or without metformin or SGLT2 inhibitor
NCT0089432212modified_ittnot statednot statednot statednot statednot statednot statedsingle_blindindustry2009adults with T2D on diet and exercise, metformin, TZD or both
AWARD-CHN126safetysevere, requiring assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2012age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-824modified_ittnot statednot statednot statednot statednot statednot stateddouble_blindindustry2013age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT02465515140.89safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2015type 2 diabetes with established cardiovascular disease
NCT0173375852safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2013Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout
NCT00359762234.81safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2006age 18 to 85; BMI 25 to below 40; HbA1c 6.5 to below 9.0 percent on maximum tolerated metformin
LIRA-SWITCH™27safetyconfirmed: severe or plasma glucose below 3.1 mmol/Lnot statednot statednot statednot statednot stateddouble_blindindustry2013age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
LixiLan-G26safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2016T2D 1 year or more; HbA1c 7 to 9 percent; BMI over 20 to 40; maximum tolerated GLP-1 RA plus metformin
AWARD-278safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2010type 2 diabetes on metformin and glimepiride
DUAL™ VIII108.29safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2016adults with type 2 diabetes uncontrolled on oral drugs, insulin naive
NCT0244960316safetynot statednot statednot statednot statednot statednot statedopen_labelmixed2015age 18 to 70, HbA1c 7.5 to 10.0 percent on metformin at least 1500 mg, BMI 21 to 35
DURATION-NEO-228safetyminor (symptomatic, glucose below 54 mg/dL) or major hypoglycemianot statednot statednot statednot statednot statedopen_labelindustry2013age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT0551453545safetylevel 3 severe hypoglycemianot statednot statednot statednot statednot statedopen_labelindustry2022adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-630safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2012adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
GetGoal-M-Asia24safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2010Asian adults with type 2 diabetes on metformin with or without sulfonylurea
NCT0398529320safetyTEAE preferred term hypoglycemia, not necessarily protocol definednot statednot statednot statednot statednot stateddouble_blindindustry2019age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT0070193526.07safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008adults with T2D on metformin
NCT0119126856safetyparticipants with serious adverse eventsnot statednot statednot statednot statednot statedopen_labelindustry2010adults with type 2 diabetes on conventional insulin with or without metformin
LixiLan-O30.29safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in
NCT0697482520safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 19.5 to 35.0; no glucose lowering drug for 8 weeks
GETGOAL-P132safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008type 2 diabetes on pioglitazone 30 mg or more with or without metformin; HbA1c 7 percent or more
SUSTAIN™ 435safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014adults with T2D, insulin naive, on metformin with or without SU; HbA1c 7.0 to 10.0 percent
NCT0037549224safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2006type 2 diabetes; weight loss trial
NCT0450439624safetysevere hypoglycemia with severe cognitive impairment needing medical treatmentnot statednot statednot statednot statednot stateddouble_blindindustry2020age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg
DUALTM IX27safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2016adults; insulin naive type 2 diabetes on SGLT2 inhibitor with or without other oral drugs; HbA1c 7.0 to 11.0 percent; BMI 20 to 40
SURPASS-4104.36safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2018age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents
NCT0087789024modified_ittnot statednot statednot statednot statednot statednot statedopen_labelindustry2009age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45
SUSTAIN35safetySevere (ADA) or glucose confirmed below 3.1 mmol/L with symptomsnot statednot statednot statednot statednot stateddouble_blindindustry2017Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT0036033426full_analysissevere: third party assistance with glucose below 2.8 mmol/L or prompt recoverynot statednot statednot statednot statednot statedopen_labelindustry2006BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
DUAL™ V27safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2013T2D uncontrolled on insulin glargine 20 to 50 U plus metformin
NCT0455247012safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2020Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
NCT0100318426modified_ittnot statednot statednot statednot statednot statednot statedopen_labelindustry2009age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
STRIDE57safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2020age 18 or more; type 2 diabetes; symptomatic PAD Fontaine IIa; ABI 0.90 or less or TBI 0.70 or less
NCT0205956418safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2013age 18 to 70; HbA1c 6.5 to 10 percent; BMI 18 to 45; metformin with or without sulfonylurea
SOLID-DKD18safetylevel 3 severe hypoglycemianot statednot statednot statednot statednot stateddouble_blindindustry2024age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
PIONEER 687safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017T2D; age 50 or more with CVD or CKD, or 60 or more with CV risk factors
AWARD-CHN252safetysevere, requiring assistance of another personnot statednot statednot statednot statednot statedopen_labelindustry2012age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
LixiLan-L30safetyserious hypoglycaemia adverse eventnot statednot statednot statednot statednot statedopen_labelindustry2014adults with T2D on basal insulin 15 to 40 U/d; HbA1c 7 to 10% and glargine 20 to 50 U after run in
NCT0232484217.38safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014T2DM, HbA1c 7 to 11 percent, eGFR 60 or more, drug naive or metformin with or without SU
NCT0091726736modified_ittnot statednot statednot statednot statednot statednot statedopen_labelindustry2009Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs
GETGOAL-X116safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2008age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT0029987113.43safetysymptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydratenot statednot statednot statednot statednot stateddouble_blindindustry2006age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
NCT0221206717randomizednot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin
SUSTAIN™62safetysevere (ADA) or symptomatic with plasma glucose below 3.1 mmol/Lnot statednot statednot statednot statednot statedopen_labelindustry2014Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
LEAD-2104.28safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2006age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin
NCT0162048927safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2012type 2 diabetes; eGFR 30 to 59 mL/min/1.73m2 (MDRD); oral drugs and/or insulin
NCT0548606549safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
DUAL™ II China30safetyEAC confirmed MACE; components not definednot statedyesnot statednot statednot stateddouble_blindindustry2017age 18 or older; BMI 24 or higher; HbA1c 7.5 or higher; basal insulin 20 to 50 U plus metformin
GETGOAL-F1112safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008adults with T2D on metformin
SURPASS-356safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2019insulin naive; HbA1c 7.0 to 10.5 percent; BMI at least 25; metformin with or without SGLT2i; eGFR above 45
NCT0046094112safetysevere hypoglycemia, undefinednot statednot statednot statednot statednot stateddouble_blindindustry2007age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
SURPASS-544safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2019HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin
NCT0332263112safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
NCT009716594modified_ittmajor hypoglycemia, subject unable to self treatnot statednot statednot statednot statednot statedopen_labelindustry2008age 35 to 70; T2D 6 months to 10 years; HbA1c 7 to 10 percent; BMI 21 to 39.9
NCT0060323926safetyparticipants with serious adverse eventsnot statednot statednot statednot statednot stateddouble_blindindustry2008type 2 diabetes on a thiazolidinedione with or without metformin
PIONEER 131safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2016adults with type 2 diabetes on diet and exercise only; HbA1c 7.0 to 9.5 percent
NCT0242026227safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2015age 18 or older; HbA1c 7.0 to 10.0; BMI up to 40; glargine 20 to 50 U plus metformin
NCT0064105684modified_ittnot statednot statednot statednot statednot statednot statedopen_labelindustry2008age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea
ELEGANT26randomizedGrade 3, needing third party assistancenot statednot statednot statednot statednot statedopen_labelindustry2012age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT0112658052safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2010type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
PIONEER 1131safetyADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all armsnot statednot statednot statednot statednot stateddouble_blindindustry2019age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
NCT0127223268safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2011adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs
NCT0094391712safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2009age 18 to 70; HbA1c 7 to 10 percent; BMI 40 or less; stable metformin 3 months
SUSTAIN 857safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated
SUSTAIN™ 535safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
SUSTAIN™ 256safetyADA severe hypoglycemianot statednot statednot statednot statednot stateddouble_blindindustry2013type 2 diabetes on metformin and or thiazolidinedione; HbA1c 7.0 to 10.5 percent
NCT0222922726safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
Rebuild12safetynot statednot statednot statednot statednot statednot statedopen_labelmixed2015age 18 to 80; T2D with HbA1c 6.5 to 12.2 percent; eligible for coronary drug eluting stent
NCT0038223912full_analysisnot statednot statednot statednot statednot statednot stateddouble_blindindustry2006age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
SUSTAIN™ 6109safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2013T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor
SURPASS-SWITCH44safetyall cause deathsnot statednot statednot statednot statednot statedopen_labelindustry2022age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg
PIONEER 957safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017Japanese adults 20 y or older; HbA1c 6.5 to 9.5 on one oral drug washed out, or 7.0 to 10.0 on diet and exercise
AGAC20.43randomizednot statednot statednot statednot statednot statednot statedopen_labelnon_industry2011age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
ACHIEVE-142safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023adults with type 2 diabetes on diet and exercise alone; HbA1c 7.0 to 9.5 percent
NCT0163216324safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2012adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
DUAL™ I Japan53safetysevere or blood glucose confirmed below 3.1 mmol/L with or without symptomsnot statednot statednot statednot statednot statedopen_labelindustry2015Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug
NCT0508644514safetyHypoglycemia adverse event of special interestnot statednot statednot statednot statednot stateddouble_blindindustry2021Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
LIXILAN JP-O152.43safetyTEAE leading to deathnot statednot statednot statednot statednot statedopen_labelindustry2016insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
GETGOAL-L125safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008adults; HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin
PIONEER 531safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2016type 2 diabetes; HbA1c 7.0 to 9.5 percent; moderate renal impairment
DUAL™ II Japan27safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2016Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin
NCT035503788.43safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2018age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent
AMPLITUDE-M56safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™35safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT0228827314modified_ittnot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less
NCT0269088324safetyPatients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuationnot statednot statednot statednot statednot statedopen_labelindustry2016age 18 or older; eGFR 30 or more; UAER above 0.3 g/24 h
LEAD-527safetynot statednot statednot statedobservednot statednot stateddouble_blindindustry2006age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
Lixilan-L-CN30.43safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2019Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT0499803224safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2021age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
AWARD-156safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2010adults with type 2 diabetes on metformin and pioglitazone
GETGOAL-M76.43safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2008type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT0145544116completersZero implied by no hypoglycemia episodes of any kindnot statednot statednot statednot statednot stateddouble_blindindustry2011age over 18; HbA1c 7 to 11 percent; BMI over 25; diet or metformin; sedentary
SIMPLE26safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2014age 18 or older; HbA1c 10 or higher; no prandial insulin, DPP-4 inhibitor or GLP-1 RA
NCT0331172416modified_ittplasma glucose 54 mg/dL or lowernot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT0504871928safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2021adults with type 2 diabetes, HbA1c 7.0 to 10.5 percent, BMI 23 or more, diet or metformin
PIONEER 383othernot statednot statednot statedobservednot statednot stateddouble_blindindustry2016adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea
DUAL™ II27safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2011HbA1c 7.5 to 10 percent; BMI 27 or higher; basal insulin 20 to 40 U plus metformin with or without SU or glinides
NCT0446690420safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2020age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
GETGOAL-MONO12.43safetysymptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydratenot statednot statednot statednot statednot stateddouble_blindindustry2008age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
NCT0211333224safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2013T2D on multiple daily insulin injections; HbA1c 7.5 to 11.5 percent; BMI 27.5 to 45 kg/m2
NCT0070081752othernot statednot statednot statednot statednot statednot statedopen_labelindustry2008age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
NCT0143240552.14safetynot statednot statednot statednot statednot statednot statedopen_labelmixed2007age 30 to 70; FPG 7.0 to 14.5 mmol/L; diet or metformin
PIONEER 857safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2017adults with type 2 diabetes on basal, premixed or basal bolus insulin with or without metformin
NCT0625652329safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more
S00285824randomizednot statednot statednot statednot statednot statednot stateddouble_blindindustryT2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S00288512othersymptomatic mild hypoglycemia, no glucose threshold printednot statednot statednot statednot statednot statedopen_labelnon_industry2019age 20 to 75; HbA1c 7.0 or more on metformin and glimepiride; eGFR 30 or more
S00294725safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2021age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S00295116safetynot statednot statednot statednot statednot statednot statedopen_labelnon_industry2022age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
NCT056548314.86safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022MAD: age 18 to 70; BMI 24 to 40; HbA1c 7.0 to 10.5 percent; T2DM on metformin or lifestyle
S00299226safetynot statednot statednot statedobservednot statednot statedopen_labelindustryadults 18 or older; HbA1c 7.5 to 10 percent; BMI 20 to less than 40; basal insulin 20 to 50 U plus metformin with or without SGLT2i
S00300924completersnot statednot statednot statednot statednot statednot statedopen_labelindustry2023age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g
S0030412full_analysisnot statednot statednot statednot statednot statednot statedopen_labelindustry2014Japanese; age 40 to 70; BMI below 30; HbA1c 6.0 to 8.5 percent
S00304424randomizednot statednot statednot statednot statednot statednot statednot_reportedmixed2015HbA1c 7.0 to <10.0%; BMI 18.5 to <25; waist >85 cm men, >80 cm women; stable oral agents
S0030476.57safetySymptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurementnot statednot statednot statednot statednot stateddouble_blindindustry2006age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S0030795safetyhypoglycemia requiring medical assistancenot statednot statednot statednot statednot statedopen_labelnon_industry2010age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months
S00343724randomizedsevere hypoglycemia needing emergency carenot statednot statednot statednot statednot statednot_reportednon_industry2025knee osteoarthritis Kellgren Lawrence I to III; obesity; metabolic syndrome; type 2 diabetes for randomized groups

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT03131687A1PLACEBO30arm, events2 / 51R0016215:Table 3
NCT03131687A2+A3+A4+A5TIRZ_SC30arm, events8 / 213arms_combinedR0016215:Table 3
NCT03131687A6DULA_SC30arm, events3 / 54R0016215:Table 3
NCT00754988A2+A3TASP_SC156arm, events36 / 388arms_combinedR0022521:Table 2
NCT00754988A4SITAGLIPTIN156arm, events19 / 185R0022521:Table 2
NCT05407961A1OTHER_ACTIVE_macupatide12arm, events0 / 15R0015193:Table 2
NCT05407961A2DULA_SC12arm, events0 / 29R0015193:Table 2
NCT05407961A3DULAMACU_SC12arm, events1 / 28R0015193:Table 2
NCT00775684A1EXEN_SC26.07arm, events0 / 17registry:adverse_events
NCT00775684A2SITAGLIPTIN26.07arm, events0 / 13registry:adverse_events
NCT00775684A3GLIMEPIRIDE26.07arm, events0 / 17registry:adverse_events
NCT02325960A1EXEN_SC16arm, events0 / 22R0024438:Results
NCT02325960A2INS_GLARGINE16arm, events0 / 23R0024438:Results
NCT00518115A1PLACEBO24arm, events2 / 52registry:adverse_events
NCT00518115A10+A3+A4+A5+A6+A7+A8+A9ALBI_SC24arm, events34 / 274arms_combinedregistry:adverse_events
NCT00518115A2EXEN_SC24arm, events1 / 35registry:adverse_events
NCT01296412A1SITAGLIPTIN26arm, events17 / 326R0026295:Table 3
NCT01296412A2LIRA_SC26arm, events12 / 327R0026295:Table 3
DUAL™ I ChinaA1IDEGLIRA_SC27arm, events14 / 361R0012560:Table 3
DUAL™ I ChinaA2INS_DEGLUDEC27arm, events7 / 179R0012560:Table 3
DUAL™ I ChinaA3LIRA_SC27arm, events14 / 180R0012560:Table 3
NCT00838916A1ALBI_SC164arm, events92 / 516registry:adverse_events
NCT00838916A2INS_GLARGINE164arm, events46 / 263registry:adverse_events
SURPASS-6A1+A2+A3TIRZ_SC56arm, events44 / 717arms_combinedR0009666:Table 3
SURPASS-6A4INS_LISPRO56arm, events77 / 711R0009666:Table 3
PIONEER 4A1SEMA_PO57arm, events31 / 285R0015836:Table 3
PIONEER 4A2LIRA_SC57arm, events22 / 284R0015836:Table 3
PIONEER 4A3PLACEBO57arm, events15 / 142R0015836:Table 3
NCT04965506A1+A2+A3MAZD_SC24arm, events3 / 149arms_combinedR0012443:Table 2
NCT04965506A4DULA_SC24arm, events4 / 50R0012443:Table 2
NCT04965506A5PLACEBO24arm, events4 / 51R0012443:Table 2
MAGNA VICTORIAA1LIRA_SC26arm, events0 / 22R0020542:Results
MAGNA VICTORIAA2PLACEBO26arm, events1 / 25R0020542:Results
REWINDA1PLACEBO365.26arm, events2,044 / 4,952registry:adverse_events
REWINDA2DULA_SC365.26arm, events1,991 / 4,949registry:adverse_events
COMBINE 2A1ICOSEMA_SC57arm, events38 / 342R0005851:Table 4
COMBINE 2A2SEMA_SC57arm, events21 / 341R0005851:Table 4
SCALE™ InsulinA1LIRA_SC58arm, events16 / 198R0024063:Table 3
SCALE™ InsulinA2PLACEBO58arm, events19 / 198R0024063:Table 3
STEP HFpEF DMA1SEMA_SC57arm, events55 / 310R0020223:Table 3
STEP HFpEF DMA2PLACEBO57arm, events88 / 306R0020223:Table 3
DUAL™IVA1IDEGLIRA_SC26arm, events14 / 289registry:adverse_events
DUAL™IVA2PLACEBO26arm, events5 / 146registry:adverse_events
Lixilan-O-APA1IGLARLIXI_SC24.43arm, events17 / 351R0013321:Table 3
Lixilan-O-APA2INS_GLARGINE24.43arm, events20 / 350R0013321:Table 3
Lixilan-O-APA3LIXI_SC24.43arm, events11 / 177R0013321:Table 3
NCT01476475A1IGLARLIXI_SC24arm, events9 / 161R0021236:Table 2
NCT01476475A2INS_GLARGINE24arm, events6 / 162R0021236:Table 2
OUTSTAND-1A1+A2+A3SAFIGL_PO32arm, events14 / 212arms_combinedR0011607:Table 3
OUTSTAND-1A4PLACEBO32arm, events1 / 72R0011607:Table 3
PB119A1VISEPE_SC24arm, events9 / 137R0011471:Table 4
PB119A2PLACEBO24arm, events2 / 136R0011471:Table 4
NCT01001104A1PLACEBO16arm, events0 / 37R0015000:Table 3
NCT01001104A2+A3+A4DULA_SC16arm, events2 / 108arms_combinedR0015000:Table 3
PIONEER 10A1+A2+A3SEMA_PO57arm, events20 / 393arms_combinedR0018421:Table 2
PIONEER 10A4DULA_SC57arm, events1 / 65R0018421:Table 2
NCT02846233A1DULA_SC52.14arm, events0 / 12registry:adverse_events
NCT02846233A2OTHER_ACTIVE_basal_bolus_insulin52.14arm, events0 / 10registry:adverse_events
AWARD-7A1INS_GLARGINE52arm, events52 / 194R0017387:Table 2
AWARD-7A2+A3DULA_SC52arm, events83 / 383arms_combinedR0017387:Table 2
NCT01584232A1DULA_SC26arm, events9 / 181R0016159:Table 3
NCT01584232A2INS_GLARGINE26arm, events3 / 180R0016159:Table 3
NCT03235050A1PLACEBO58arm, events12 / 112registry:adverse_events
NCT03235050A2LIRA_SC58arm, events8 / 110registry:adverse_events
NCT03235050A3+A4+A5COTA_SC58arm, events65 / 612arms_combinedregistry:adverse_events
NCT04235959A1PLACEBO28arm, events1 / 4R0019570:Table 2
NCT04235959A3TIRZ_SC28arm, events0 / 10R0019570:Table 2
AWARD-10A1+A2DULA_SC24arm, events8 / 284arms_combinedR0020348:p1
AWARD-10A3PLACEBO24arm, events5 / 140R0020348:p1
SUSTAIN™ 3A1SEMA_SC61arm, events38 / 406R0020680:Supplement Table S5
SUSTAIN™ 3A2EXENER_SC61arm, events24 / 407R0020680:Supplement Table S5
NCT00393718A1LIRA_SC52arm, events20 / 272registry:adverse_events
NCT00393718A2GLIBENCLAMIDE52arm, events14 / 139registry:adverse_events
EGOA1+A2+A3DULA_SC16arm, events6 / 196arms_combinedregistry:adverse_events
EGOA4PLACEBO16arm, events1 / 66registry:adverse_events
NCT00765817A1EXEN_SC30arm, events8 / 138R0027069:Table 3
NCT00765817A2PLACEBO30arm, events11 / 123R0027069:Table 3
NCT01029886A1EXENER_SC26arm, events13 / 461R0016299:Table 3
NCT01029886A2LIRA_SC26arm, events7 / 451R0016299:Table 3
LIXILAN JP-LA1IGLARLIXI_SC26.43arm, events6 / 255R0008233:Supplement Table S1
LIXILAN JP-LA2INS_GLARGINE26.43arm, events11 / 257R0008233:Supplement Table S1
SUSTAIN 11A1SEMA_SC52arm, events65 / 874R0022346:Table 3
SUSTAIN 11A2INS_ASPART52arm, events84 / 874R0022346:Table 3
NCT02765399A1LIRA_SC16arm, events0 / 16registry:adverse_events
NCT02765399A2PLACEBO16arm, events0 / 7registry:adverse_events
SUSTAIN 7A1+A2SEMA_SC45arm, events40 / 601arms_combinedregistry:adverse_events
SUSTAIN 7A3+A4DULA_SC45arm, events46 / 600arms_combinedregistry:adverse_events
NCT00791479A1+A2+A3+A4+A5DULA_SC12arm, events3 / 135arms_combinedregistry:adverse_events
NCT00791479A6PLACEBO12arm, events1 / 32registry:adverse_events
NCT03010683A1LIRA_SC52.14arm, events0 / 30registry:adverse_events
NCT03010683A2METFORMIN52.14arm, events0 / 30registry:adverse_events
REMODELA1SEMA_SC57arm, events14 / 71R0007381:Extended Data Table 5
REMODELA2PLACEBO57arm, events5 / 35R0007381:Extended Data Table 5
NCT00637273A1EXENER_SC26arm, events4 / 170registry:adverse_events
NCT00637273A2SITAGLIPTIN26arm, events5 / 172registry:adverse_events
NCT00637273A3PIOGLITAZONE26arm, events10 / 172registry:adverse_events
SURPASS-1A1+A2+A3TIRZ_SC44arm, events8 / 363arms_combinedregistry:adverse_events
SURPASS-1A4PLACEBO44arm, events3 / 115registry:adverse_events
NCT00717457A1+A2TASP_SC104arm, events83 / 797arms_combinedR0013639:Table 2
NCT00717457A3EXEN_SC104arm, events38 / 392R0013639:Table 2
NCT00976937A1LIXI_SC24arm, events3 / 158R0012687:Table 2
NCT00976937A2SITAGLIPTIN24arm, events3 / 161R0012687:Table 2
NCT00516074A1EXEN_SC12arm, events1 / 28registry:adverse_events
NCT00516074A2PLACEBO12arm, events1 / 26registry:adverse_events
ACHIEVE-3A1+A2ORFO_PO57arm, events61 / 847arms_combinedregistry:adverse_events
ACHIEVE-3A3+A4SEMA_PO57arm, events43 / 851arms_combinedregistry:adverse_events
NCT00082407A1EXEN_SC52arm, events19 / 255R0025791:Table 3
NCT00082407A2INS_PREMIX52arm, events11 / 250R0025791:Table 3
AWARD-9A1DULA_SC28arm, events9 / 150registry:adverse_events
AWARD-9A2PLACEBO28arm, events7 / 150registry:adverse_events
NCT05579977A1+A8PLACEBO28arm, events2 / 139arms_combinedR0004106:Supplement Table S3
NCT05579977A10+A11+A12+A13+A2+A3+A4+A5+A6+A9LOTI_PO28arm, events18 / 690arms_combinedR0004106:Supplement Table S3
NCT05579977A7SEMA_PO28arm, events1 / 73R0004106:Supplement Table S3
COMBINE 1A1ICOSEMA_SC57arm, events59 / 646registry:adverse_events
COMBINE 1A2INS_ICODEC57arm, events69 / 645registry:adverse_events
TRANSITION-T2DA1OTHER_ACTIVE_basal_bolus_insulin26arm, events4 / 20R0018231:Table 2
TRANSITION-T2DA2SEMA_SC26arm, events9 / 40R0018231:Table 2
SUSTAIN 9A1SEMA_SC36arm, events7 / 151R0021710:Table 2
SUSTAIN 9A2PLACEBO36arm, events6 / 151R0021710:Table 2
GETGOAL-L-ASIAA1LIXI_SC24arm, events10 / 154R0022626:Table 2
GETGOAL-L-ASIAA2PLACEBO24arm, events9 / 157R0022626:Table 2
NCT04867785A1PLACEBO40arm, events3 / 45registry:adverse_events
NCT04867785A2DULA_SC40arm, events1 / 46registry:adverse_events
NCT04867785A3+A4+A5+A6+A7+A8RETA_SC40arm, events11 / 190arms_combinedregistry:adverse_events
GETGOAL-SA1PLACEBO120arm, events35 / 286registry:adverse_events
GETGOAL-SA2LIXI_SC120arm, events58 / 573registry:adverse_events
LIRA-PRIMEA1LIRA_SC105arm, events92 / 996R0022482:Table 3
LIRA-PRIMEA2OTHER_ACTIVE_investigator_choice_oral_drug105arm, events81 / 995R0022482:Table 3
PIONEER 12A1+A2+A3SEMA_PO31arm, events38 / 1,082arms_combinedR0019776:Table 3
PIONEER 12A4SITAGLIPTIN31arm, events15 / 359R0019776:Table 3
NCT00612794A1PLACEBO20arm, events0 / 10printed_denominatorR0027116:p5
NCT00612794A2+A3EXENER_SC20arm, events0 / 19printed_denominator;arms_combinedR0027116:p5
NCT03596450A1SEMA_SC104arm, events38 / 644registry:adverse_events
NCT03596450A2STANDARD_CARE104arm, events39 / 634registry:adverse_events
NCT06589765A1+A2+A3SAFIGL_PO52arm, events43 / 608arms_combinedR0029347:Table 3
NCT06589765A4DAPAGLIFLOZIN52arm, events18 / 202R0029347:Table 3
SUSTAIN 10A1SEMA_SC35arm, events17 / 290registry:adverse_events
SUSTAIN 10A2LIRA_SC35arm, events22 / 287registry:adverse_events
NCT01175473A1LIXI_SC4.43arm, events0 / 77R0022723:Table 3
NCT01175473A2LIRA_SC4.43arm, events0 / 71R0022723:Table 3
NCT03951753A1TIRZ_SC32arm, events1 / 45registry:adverse_events
NCT03951753A2SEMA_SC32arm, events0 / 44registry:adverse_events
NCT03951753A3PLACEBO32arm, events2 / 28registry:adverse_events
NCT00960661A1EXEN_SC30arm, events18 / 316R0016788:Supplement Table 4
NCT00960661A2INS_LISPRO30arm, events23 / 321R0016788:Supplement Table 4
NCT00935532A1EXENER_SC26arm, events6 / 215registry:adverse_events
NCT00935532A2INS_GLARGINE26arm, events5 / 212registry:adverse_events
NCT02008682A1LIRA_SC26arm, events3 / 184R0025836:Table 2
NCT02008682A2SITAGLIPTIN26arm, events6 / 184R0025836:Table 2
NCT03555994A1PLACEBO9arm, events0 / 11R0005744:Table 2
NCT03555994A2LIRA_SC9arm, events0 / 10R0005744:Table 2
NCT03555994A3COTA_SC9arm, events0 / 9R0005744:Table 2
NCT03829891A1BEIN_SC16arm, events0 / 35R0007581:Results
NCT03829891A2INS_GLARGINE16arm, events0 / 33R0007581:Results
NCT02229383A1EXENER_SC38arm, events11 / 233R0014763:Table 3
NCT02229383A2PLACEBO38arm, events11 / 231R0014763:Table 3
NCT02081118A1PLACEBO22arm, events2 / 51R0009733:Table 3
NCT02081118A2+A3+A4EFPE_SC22arm, events8 / 157printed_denominator;arms_combinedR0009733:Table 3
NCT00577824A1PLACEBO24arm, events4 / 36R0018881:Results
NCT00577824A2+A3EXEN_SC24arm, events2 / 145arms_combinedR0018881:Results
ATTAIN-2A1PLACEBO74arm, events55 / 630registry:adverse_events
ATTAIN-2A2+A3+A4ORFO_PO74arm, events93 / 983arms_combinedregistry:adverse_events
NCT02973321A1PLACEBO26.4arm, events0 / 33registry:adverse_events
NCT02973321A5LIRA_SC26.4arm, events2 / 67registry:adverse_events
NCT01149421A1+A2DULA_SC26arm, events20 / 505arms_combinedregistry:adverse_events
NCT01149421A3PLACEBO26arm, events8 / 250registry:adverse_events
NCT00434954A1EXEN_SC26arm, events9 / 248registry:adverse_events
NCT00434954A2INS_PREMIX26arm, events8 / 246registry:adverse_events
NCT02229396A1DAPAEXEN_SC104arm, events17 / 231registry:adverse_events
NCT02229396A2EXENER_SC104arm, events18 / 231registry:adverse_events
NCT02229396A3DAPAGLIFLOZIN104arm, events18 / 233registry:adverse_events
GetGoal-Duo1A1PLACEBO24.43arm, events10 / 223registry:adverse_events
GetGoal-Duo1A2LIXI_SC24.43arm, events17 / 223registry:adverse_events
NCT01558271A1DULA_SC52arm, events9 / 281R0011754:Table 2
NCT01558271A2LIRA_SC52arm, events7 / 141R0011754:Table 2
NCT00849017A1PLACEBO164arm, events16 / 105registry:adverse_events
NCT00849017A2+A3ALBI_SC164arm, events29 / 204arms_combinedregistry:adverse_events
NCT00395746A1+A2LIRA_SC52arm, events7 / 178arms_combinedR0022802:Results
NCT00395746A3PLACEBO52arm, events5 / 89R0022802:Results
NCT01147627A1EXEN_SC48arm, events5 / 142registry:adverse_events
NCT01147627A2INS_PREMIX48arm, events1 / 138registry:adverse_events
NCT01147627A3PIOGLITAZONE48arm, events7 / 136registry:adverse_events
GRADEA1INS_GLARGINE365.26arm, events259 / 1,263registry:adverse_events
GRADEA2GLIMEPIRIDE365.26arm, events315 / 1,254registry:adverse_events
GRADEA3LIRA_SC365.26arm, events204 / 1,262registry:adverse_events
GRADEA4SITAGLIPTIN365.26arm, events272 / 1,268registry:adverse_events
NCT05759897A1PLACEBO18arm, events2 / 39printed_denominatorR0002101:Supplement eTable 9
NCT05759897A2+A3+A4+A5SAFIGL_PO18arm, events4 / 155printed_denominator;arms_combinedR0002101:Supplement eTable 9
SUSTAIN™1A1+A2SEMA_SC35arm, events14 / 259arms_combinedR0021710:Table 2
SUSTAIN™1A3PLACEBO35arm, events5 / 129R0021710:Table 2
GetGoal-OA1LIXI_SC24.43arm, events8 / 176registry:adverse_events
GetGoal-OA2PLACEBO24.43arm, events10 / 174registry:adverse_events
NCT01144338A1PLACEBO391.35arm, events1,222 / 7,396registry:adverse_events
NCT01144338A2EXENER_SC391.35arm, events1,234 / 7,356registry:adverse_events
NCT04093752A1+A2+A3TIRZ_SC44arm, events44 / 687arms_combinedregistry:adverse_events
NCT04093752A4INS_GLARGINE44arm, events20 / 230registry:adverse_events
NCT01617434A1LIRA_SC27arm, events11 / 226R0026247:Table 3
NCT01617434A2PLACEBO27arm, events7 / 225R0026247:Table 3
NCT00135330A1EXEN_SC20arm, events3 / 45registry:adverse_events
NCT00135330A2EXENROSI_SC20arm, events4 / 47registry:adverse_events
NCT00135330A3ROSIGLITAZONE20arm, events4 / 45registry:adverse_events
LIRA-Ramadan™A1LIRA_SC30arm, events5 / 172R0025756:Supplement Table S2
LIRA-Ramadan™A2OTHER_ACTIVE_sulfonylurea30arm, events2 / 171R0025756:Supplement Table S2
NCT02200991A1LIXI_SC4.43arm, events0 / 69R0024589:Table 3
NCT02200991A2SITAGLIPTIN4.43arm, events0 / 67R0024589:Table 3
NCT00097500A1EXEN_SC64arm, events3 / 36registry:adverse_events
NCT00097500A2INS_GLARGINE64arm, events1 / 33registry:adverse_events
ACHIEVE-5A1PLACEBO42arm, events6 / 141registry:adverse_events
ACHIEVE-5A2+A3+A4ORFO_PO42arm, events26 / 405arms_combinedregistry:adverse_events
NCT00894322A1EXENER_SC12arm, events0 / 23registry:outcomes
NCT00894322A2PLACEBO12arm, events1 / 12registry:outcomes
AWARD-CHN1A1+A2DULA_SC26arm, events10 / 492arms_combinedR0014229:Table 2
AWARD-CHN1A3GLIMEPIRIDE26arm, events3 / 245R0014229:Table 2
AWARD-8A1DULA_SC24arm, events9 / 240R0016038:Table 2
AWARD-8A2PLACEBO24arm, events0 / 60R0016038:Table 2
NCT02465515A1PLACEBO140.89arm, events1,022 / 4,732registry:adverse_events
NCT02465515A2ALBI_SC140.89arm, events932 / 4,731registry:adverse_events
NCT01733758A2+A3ALBI_SC52arm, events11 / 310printed_denominator;arms_combinedR0010997:Table 2
NCT01733758A4LIRA_SC52arm, events0 / 103printed_denominatorR0010997:Table 2
NCT00359762A1EXEN_SC234.81arm, events73 / 515registry:adverse_events
NCT00359762A2GLIMEPIRIDE234.81arm, events68 / 514registry:adverse_events
LIRA-SWITCH™A1LIRA_SC27arm, events6 / 203R0025720:Table 1
LIRA-SWITCH™A2SITAGLIPTIN27arm, events7 / 204R0025720:Table 1
LixiLan-GA1IGLARLIXI_SC26arm, events10 / 257R0003966:Results
LixiLan-GA2GLP1RE_SC26arm, events9 / 257R0003966:Results
AWARD-2A1+A2DULA_SC78arm, events60 / 545arms_combinedregistry:adverse_events
AWARD-2A3INS_GLARGINE78arm, events33 / 265registry:adverse_events
DUAL™ VIIIA1IDEGLIRA_SC108.29arm, events60 / 506registry:adverse_events
DUAL™ VIIIA2INS_GLARGINE108.29arm, events43 / 506registry:adverse_events
NCT02449603A1EXEN_SC16arm, events4 / 52printed_denominatorR0023224:Table 3
NCT02449603A2INS_PREMIX16arm, events3 / 52printed_denominatorR0023224:Table 3
DURATION-NEO-2A1EXENER_SC28arm, events5 / 182R0010641:Table 3
DURATION-NEO-2A2SITAGLIPTIN28arm, events0 / 122R0010641:Table 3
DURATION-NEO-2A3PLACEBO28arm, events2 / 61R0010641:Table 3
NCT05514535A1SEMA_SC45arm, events17 / 288R0015842:Table 2
NCT05514535A2INS_GLARGINE45arm, events15 / 285R0015842:Table 2
AWARD-6A1DULA_SC30arm, events5 / 299registry:adverse_events
AWARD-6A2LIRA_SC30arm, events11 / 300registry:adverse_events
GetGoal-M-AsiaA1PLACEBO24arm, events4 / 195registry:adverse_events
GetGoal-M-AsiaA2LIXI_SC24arm, events3 / 196registry:adverse_events
NCT03985293A1PLACEBO20arm, events1 / 66R0006095:Table 3
NCT03985293A2+A3+A4+A5+A6DANU_PO20arm, events12 / 346arms_combinedR0006095:Table 3
NCT00701935A1EXEN_SC26.07arm, events3 / 43registry:adverse_events
NCT00701935A2PLACEBO26.07arm, events1 / 37registry:adverse_events
NCT01191268A1+A2DULA_SC56arm, events73 / 588arms_combinedregistry:adverse_events
NCT01191268A3INS_GLARGINE56arm, events53 / 296registry:adverse_events
LixiLan-OA1IGLARLIXI_SC30.29arm, events18 / 469registry:adverse_events
LixiLan-OA2INS_GLARGINE30.29arm, events19 / 467registry:adverse_events
LixiLan-OA3LIXI_SC30.29arm, events9 / 234R0014829:Table 1
NCT06974825A1+A2+A3BGM050_SC20arm, events2 / 38arms_combinedR0015161:Supplement Appendix D.1
NCT06974825A4SEMA_SC20arm, events0 / 16R0015161:Supplement Appendix D.1
NCT06974825A5PLACEBO20arm, events0 / 13R0015161:Supplement Appendix D.1
GETGOAL-PA1PLACEBO132arm, events15 / 161registry:adverse_events
GETGOAL-PA2LIXI_SC132arm, events25 / 323registry:adverse_events
SUSTAIN™ 4A1+A2SEMA_SC35arm, events39 / 722printed_denominator;arms_combinedregistry:adverse_events
SUSTAIN™ 4A3INS_GLARGINE35arm, events18 / 360printed_denominatorregistry:adverse_events
NCT00375492A1EXEN_SC24arm, events2 / 96registry:adverse_events
NCT00375492A2PLACEBO24arm, events2 / 98registry:adverse_events
NCT04504396A1VISEPE_SC24arm, events9 / 310R0009432:Table 3
NCT04504396A2PLACEBO24arm, events12 / 310R0009432:Table 3
DUALTM IXA1IDEGLIRA_SC27arm, events6 / 210R0014323:Table 3
DUALTM IXA2INS_GLARGINE27arm, events7 / 210R0014323:Table 3
SURPASS-4A1+A2+A3TIRZ_SC104.36arm, events143 / 997arms_combinedregistry:adverse_events
SURPASS-4A4INS_GLARGINE104.36arm, events193 / 1,005registry:adverse_events
NCT00877890A1EXENER_SC24arm, events3 / 129registry:adverse_events
NCT00877890A2EXEN_SC24arm, events5 / 125registry:adverse_events
SUSTAINA1+A2SEMA_SC35arm, events36 / 578arms_combinedR0014802:Table 3
SUSTAINA3SITAGLIPTIN35arm, events12 / 290R0014802:Table 3
NCT00360334A1EXEN_SC26arm, events5 / 118R0024925:Table 3
NCT00360334A2INS_GLARGINE26arm, events5 / 117R0024925:Table 3
DUAL™ VA1IDEGLIRA_SC27arm, events5 / 278registry:adverse_events
DUAL™ VA2INS_GLARGINE27arm, events9 / 279registry:adverse_events
NCT04552470A1PLACEBO12arm, events0 / 9R0004540:Supplement Table S1
NCT04552470A2+A3+A4DANU_PO12arm, events0 / 28arms_combinedR0004540:Supplement Table S1
NCT01003184A1EXENER_SC26arm, events6 / 111R0027663:Table 2
NCT01003184A2INS_DETEMIR26arm, events6 / 111R0027663:Table 2
STRIDEA1SEMA_SC57arm, events74 / 396registry:adverse_events
STRIDEA2PLACEBO57arm, events78 / 396registry:adverse_events
NCT02059564A1+A3EFPE_SC18arm, events0 / 26arms_combinedR0008346:Results
NCT02059564A2+A4PLACEBO18arm, events0 / 8arms_combinedR0008346:Results
NCT02059564A5LIRA_SC18arm, events0 / 13R0008346:Results
SOLID-DKDA1+A2HRS7535_PO18arm, events9 / 187arms_combinedR0004355:Table 2
SOLID-DKDA3PLACEBO18arm, events2 / 94R0004355:Table 2
PIONEER 6A1SEMA_PO87arm, events301 / 1,591registry:adverse_events
PIONEER 6A2PLACEBO87arm, events358 / 1,592registry:adverse_events
AWARD-CHN2A1+A2DULA_SC52arm, events39 / 515arms_combinedR0023722:Table 2
AWARD-CHN2A3INS_GLARGINE52arm, events9 / 259R0023722:Table 2
LixiLan-LA1IGLARLIXI_SC30arm, events20 / 367registry:adverse_events
LixiLan-LA2INS_GLARGINE30arm, events18 / 369registry:adverse_events
NCT02324842A1CANAGLIFLOZIN17.38arm, events1 / 15registry:adverse_events
NCT02324842A2LIRA_SC17.38arm, events0 / 15registry:adverse_events
NCT02324842A3CANALIRA_SC17.38arm, events0 / 15registry:adverse_events
NCT00917267A1EXENER_SC36arm, events13 / 340printed_denominatorregistry:adverse_events
NCT00917267A2EXEN_SC36arm, events8 / 338printed_denominatorregistry:adverse_events
GETGOAL-XA1LIXI_SC116arm, events26 / 320registry:adverse_events
GETGOAL-XA2EXEN_SC116arm, events22 / 319registry:adverse_events
NCT00299871A1PLACEBO13.43arm, events3 / 109R0021613:Table 3
NCT00299871A2+A3+A4+A5+A6+A7+A8+A9LIXI_SC13.43arm, events8 / 433arms_combinedR0021613:Table 3
NCT02212067A1SEMA_SC17arm, events2 / 37R0021892:Supplement Table 2
NCT02212067A2PLACEBO17arm, events0 / 38R0021892:Supplement Table 2
SUSTAIN™A1+A2SEMA_SC62arm, events31 / 480arms_combinedR0025024:Table 2
SUSTAIN™A3OTHER_ACTIVE_additional_OAD62arm, events8 / 121R0025024:Table 2
LEAD-2A1+A2+A3LIRA_SC104.28arm, events77 / 725arms_combinedregistry:adverse_events
LEAD-2A4GLIMEPIRIDE104.28arm, events24 / 244registry:adverse_events
LEAD-2A5PLACEBO104.28arm, events9 / 122registry:adverse_events
NCT01620489A1LIRA_SC27arm, events14 / 140registry:adverse_events
NCT01620489A2PLACEBO27arm, events15 / 139registry:adverse_events
NCT05486065A1+A2+A3SEMA_SC49arm, events7 / 185arms_combinedR0005510:Table 2
NCT05486065A4PLACEBO49arm, events2 / 60R0005510:Table 2
DUAL™ II ChinaA1IDEGLIRA_SC30arm, events13 / 302R0012135:Table 3
DUAL™ II ChinaA2INS_DEGLUDEC30arm, events7 / 151R0012135:Table 3
GETGOAL-F1A1PLACEBO112arm, events22 / 160printed_denominatorregistry:adverse_events
GETGOAL-F1A2+A3LIXI_SC112arm, events37 / 322arms_combinedregistry:adverse_events
SURPASS-3A1+A2+A3TIRZ_SC56arm, events75 / 1,079arms_combinedR0015264:Table 2
SURPASS-3A4INS_DEGLUDEC56arm, events22 / 365registry:adverse_events
NCT00460941A1PLACEBO12arm, events1 / 32printed_denominatorR0021258:Results
NCT00460941A2+A3+A4TASP_SC12arm, events1 / 97printed_denominator;arms_combinedR0021258:Results
SURPASS-5A1+A2+A3TIRZ_SC44arm, events31 / 355arms_combinedregistry:adverse_events
SURPASS-5A4PLACEBO44arm, events10 / 120registry:adverse_events
NCT03322631A1PLACEBO12arm, events0 / 9R0021917:Results
NCT03322631A2+A3+A4TIRZ_SC12arm, events0 / 39arms_combinedR0021917:Results
NCT00971659A1EXEN_SC4arm, events0 / 16R0027899:Results
NCT00971659A2SITAGLIPTIN4arm, events0 / 16R0027899:Results
NCT00971659A3STANDARD_CARE4arm, events0 / 16R0027899:Results
NCT00603239A1EXEN_SC26arm, events1 / 111registry:adverse_events
NCT00603239A2PLACEBO26arm, events0 / 54registry:adverse_events
PIONEER 1A1+A2+A3SEMA_PO31arm, events10 / 525arms_combinedregistry:adverse_events
PIONEER 1A4PLACEBO31arm, events8 / 178registry:adverse_events
NCT02420262A1IDEGLIRA_SC27arm, events12 / 252registry:adverse_events
NCT02420262A2OTHER_ACTIVE_basal_bolus_insulin27arm, events10 / 254registry:adverse_events
NCT00641056A1EXENER_SC84arm, events22 / 233R0027747:Table 1
NCT00641056A2INS_GLARGINE84arm, events23 / 234R0027747:Table 1
ELEGANTA1LIRA_SC26arm, events0 / 26R0025175:Results
ELEGANTA2STANDARD_CARE26arm, events0 / 24R0025175:Results
NCT01126580A1+A2DULA_SC52arm, events35 / 539arms_combinedregistry:adverse_events
NCT01126580A3METFORMIN52arm, events16 / 268registry:adverse_events
PIONEER 11A1+A2+A3SEMA_PO31arm, events21 / 390arms_combinedR0019663:Table 3
PIONEER 11A4PLACEBO31arm, events2 / 131R0019663:Table 3
NCT01272232A1+A2LIRA_SC68arm, events55 / 634arms_combinedR0026209:Table 7
NCT01272232A3PLACEBO68arm, events13 / 212R0026209:Table 7
NCT00943917A1+A2EXENIMP_IMPLANT12arm, events1 / 102arms_combinedregistry:adverse_events
NCT00943917A3EXEN_SC12arm, events0 / 53registry:adverse_events
SUSTAIN 8A1SEMA_SC57arm, events18 / 394registry:adverse_events
SUSTAIN 8A2CANAGLIFLOZIN57arm, events21 / 394registry:adverse_events
SUSTAIN™ 5A1+A2SEMA_SC35arm, events20 / 264arms_combinedR0012671:Table 2
SUSTAIN™ 5A3PLACEBO35arm, events9 / 133R0012671:Table 2
SUSTAIN™ 2A1+A2SEMA_SC56arm, events60 / 818printed_denominator;arms_combinedR0021710:Table 2
SUSTAIN™ 2A3SITAGLIPTIN56arm, events29 / 407printed_denominatorR0021710:Table 2
NCT02229227A1ALBI_SC26arm, events23 / 402registry:outcomes
NCT02229227A2INS_LISPRO26arm, events31 / 412registry:outcomes
RebuildA1EXENER_SC12arm, events0 / 20R0014366:Results
RebuildA2STANDARD_CARE12arm, events0 / 18R0014366:Results
NCT00382239A1PLACEBO12arm, events0 / 40R0027621:p7
NCT00382239A2+A3+A4EXEN_SC12arm, events1 / 113arms_combinedR0027621:p7
SUSTAIN™ 6A1+A2SEMA_SC109arm, events565 / 1,648arms_combinedregistry:adverse_events
SUSTAIN™ 6A3+A4PLACEBO109arm, events627 / 1,649arms_combinedregistry:adverse_events
SURPASS-SWITCHA1TIRZ_SC44arm, events10 / 139registry:adverse_events
SURPASS-SWITCHA2DULA_SC44arm, events10 / 143registry:adverse_events
PIONEER 9A1+A2+A3SEMA_PO57arm, events5 / 146arms_combinedregistry:adverse_events
PIONEER 9A4LIRA_SC57arm, events0 / 48registry:adverse_events
PIONEER 9A5PLACEBO57arm, events3 / 49registry:adverse_events
AGAC2A1PLACEBO0.43arm, events0 / 21R0020827:Supplement Table 2
AGAC2A2EXEN_SC0.43arm, events0 / 30R0020827:Supplement Table 2
ACHIEVE-1A1PLACEBO42arm, events5 / 138registry:adverse_events
ACHIEVE-1A2+A3+A4ORFO_PO42arm, events19 / 421arms_combinedregistry:adverse_events
NCT01632163A1LIXI_SC24arm, events11 / 224R0014725:Table 3
NCT01632163A2PLACEBO24arm, events2 / 224R0014725:Table 3
DUAL™ I JapanA1IDEGLIRA_SC53arm, events17 / 275R0014857:Table 2
DUAL™ I JapanA2INS_DEGLUDEC53arm, events13 / 271R0014857:Table 2
DUAL™ I JapanA3LIRA_SC53arm, events14 / 273R0014857:Table 2
NCT05086445A1PLACEBO14arm, events0 / 11R0003844:Table 2
NCT05086445A2+A3+A4ORFO_PO14arm, events0 / 49arms_combinedR0003844:Table 2
LIXILAN JP-O1A1IGLARLIXI_SC52.43arm, events7 / 161R0015751:Table 3
LIXILAN JP-O1A2LIXI_SC52.43arm, events13 / 160R0015751:Table 3
GETGOAL-LA1PLACEBO125arm, events17 / 167registry:adverse_events
GETGOAL-LA2LIXI_SC125arm, events46 / 329registry:adverse_events
PIONEER 5A1SEMA_PO31arm, events17 / 163registry:adverse_events
PIONEER 5A2PLACEBO31arm, events17 / 161registry:adverse_events
DUAL™ II JapanA1IDEGLIRA_SC27arm, events3 / 105R0015589:Table 2
DUAL™ II JapanA2INS_DEGLUDEC27arm, events4 / 105R0015589:Table 2
NCT03550378A1COTA_SC8.43arm, events2 / 21R0019218:Table 2
NCT03550378A2PLACEBO8.43arm, events2 / 20R0019218:Table 2
AMPLITUDE-MA1+A2+A3EFPE_SC56arm, events23 / 304arms_combinedR0007136:Table 2
AMPLITUDE-MA4PLACEBO56arm, events9 / 102R0007136:Table 2
SUSTAIN™A1+A2SEMA_SC35arm, events8 / 205arms_combinedR0014736:Table 2
SUSTAIN™A3SITAGLIPTIN35arm, events2 / 103R0014736:Table 2
NCT02288273A1EXENER_SC14arm, events4 / 61R0025397:Results
NCT02288273A2PLACEBO14arm, events1 / 56R0025397:Results
NCT02690883A1INS_LISPRO24arm, events4 / 46R0011086:Results
NCT02690883A2EXEN_SC24arm, events1 / 46R0011086:Results
LEAD-5A1LIRA_SC27arm, events9 / 232count_from_percentR0027336:Results
LEAD-5A2PLACEBO27arm, events8 / 115count_from_percentR0027336:Results
LEAD-5A3INS_GLARGINE27arm, events16 / 234count_from_percentR0027336:Results
Lixilan-L-CNA1IGLARLIXI_SC30.43arm, events15 / 212R0014540:Table 3
Lixilan-L-CNA2INS_GLARGINE30.43arm, events15 / 214R0014540:Table 3
NCT04998032A1EFSUBA_SC24arm, events5 / 171R0006975:Table 3
NCT04998032A2PLACEBO24arm, events5 / 173R0006975:Table 3
AWARD-1A1+A2DULA_SC56arm, events40 / 559arms_combinedregistry:adverse_events
AWARD-1A3EXEN_SC56arm, events27 / 278registry:adverse_events
GETGOAL-MA1+A2LIXI_SC76.43arm, events47 / 510arms_combinedregistry:adverse_events
GETGOAL-MA3PLACEBO76.43arm, events11 / 170printed_denominatorregistry:adverse_events
NCT01455441A1LIRA_SC16arm, events0 / 18R0010221:Results
NCT01455441A2PLACEBO16arm, events0 / 16R0010221:Results
SIMPLEA1INS_ASPART26arm, events13 / 61registry:adverse_events
SIMPLEA2LIRA_SC26arm, events6 / 59registry:adverse_events
NCT03311724A1PLACEBO16arm, events0 / 26R0010282:Table 2
NCT03311724A2+A3+A4TIRZ_SC16arm, events1 / 85arms_combinedR0010282:Table 2
NCT05048719A1PLACEBO28arm, events3 / 55registry:adverse_events
NCT05048719A2+A3+A4+A5+A6+A7+A8ORFO_PO28arm, events12 / 278arms_combinedregistry:adverse_events
NCT05048719A9DULA_SC28arm, events1 / 50registry:adverse_events
PIONEER 3A1+A2+A3SEMA_PO83arm, events155 / 1,397count_from_percent;arms_combinedR0024670:Abstract
PIONEER 3A4SITAGLIPTIN83arm, events58 / 467count_from_percentR0024670:Abstract
DUAL™ IIA1IDEGLIRA_SC27arm, events7 / 207registry:adverse_events
DUAL™ IIA2INS_DEGLUDEC27arm, events11 / 206registry:adverse_events
NCT04466904A1+A2+A3MAZD_SC20arm, events2 / 24arms_combinedR0009340:Table 2
NCT04466904A4DULA_SC20arm, events0 / 6printed_denominatorR0009340:Table 2
NCT04466904A5PLACEBO20arm, events0 / 12printed_denominatorR0009340:Table 2
GETGOAL-MONOA1PLACEBO12.43arm, events5 / 122printed_denominatorR0022843:Table 2
GETGOAL-MONOA2+A3LIXI_SC12.43arm, events1 / 239arms_combinedR0022843:Table 2
NCT02113332A1LIRA_SC24arm, events3 / 64R0026157:Table 3
NCT02113332A2PLACEBO24arm, events4 / 60R0026157:Table 3
NCT00700817A1+A2LIRA_SC52arm, events23 / 446arms_combinedR0024199:Table 2
NCT00700817A3SITAGLIPTIN52arm, events12 / 219R0024199:Table 2
NCT01432405A1EXEN_SC52.14arm, events0 / 12registry:adverse_events
NCT01432405A2STANDARD_CARE52.14arm, events0 / 12registry:adverse_events
PIONEER 8A1+A2+A3SEMA_PO57arm, events56 / 547arms_combinedregistry:adverse_events
PIONEER 8A4PLACEBO57arm, events17 / 184registry:adverse_events
NCT06256523A1BOFANG_SC29arm, events1 / 27printed_denominatorR0002476:Table 2
NCT06256523A2PLACEBO29arm, events0 / 9printed_denominatorR0002476:Table 2
S002858A1LIXI_SC24arm, events5 / 51R0001573:Supplement Table S2
S002858A2PLACEBO24arm, events3 / 50R0001573:Supplement Table S2
S002885A1DULA_SC12arm, events0 / 13R0003420:Results
S002885A2EMPAGLIFLOZIN12arm, events0 / 12R0003420:Results
S002947A1+A2+A3ECNO_SC25arm, events1 / 109arms_combinedR0006482:Table 2
S002947A4PLACEBO25arm, events0 / 36R0006482:Table 2
S002951A1PEGLOX_SC16arm, events3 / 104R0007588:Table 3
S002951A2METFORMIN16arm, events1 / 52R0007588:Table 3
NCT05654831A1+A2+A3+A4ECC500_PO4.86arm, events0 / 39arms_combinedR0007796:Table 2
NCT05654831A5PLACEBO4.86arm, events0 / 13R0007796:Table 2
S002992A1IGLARLIXI_SC26arm, events12 / 443count_from_percentR0010673:Results
S002992A2INS_PREMIX26arm, events13 / 444count_from_percentR0010673:Results
S003009A1PEGLOX_SC24arm, events1 / 44R0011381:Table 4
S003009A2DAPAGLIFLOZIN24arm, events1 / 44R0011381:Table 4
S003041A1LINAGLIPTIN2arm, events0 / 18R0020035:Results
S003041A2LIRA_SC2arm, events0 / 17R0020035:Results
S003044A1EXEN_SC24arm, events1 / 49R0023353:Results
S003044A2INS_PREMIX24arm, events1 / 46R0023353:Results
S003047A1+A2LIXI_SC6.57arm, events1 / 80printed_denominator;arms_combinedR0016337:Table 3
S003047A3PLACEBO6.57arm, events1 / 40printed_denominatorR0016337:Table 3
S003079A1EXEN_SC5arm, events0 / 18R0025923:Results
S003079A2STANDARD_CARE5arm, events0 / 18R0025923:Results
S003437A1METFORMIN24arm, events0 / 60R0053478:Results
S003437A2+A3SEMA_SC24arm, events0 / 120arms_combinedR0053478:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab